{
  "name" : "dacemirror.sci-hub.se_journal-article_ffac6e1005b53ff6159fc152d3d6edad_wang2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design",
    "authors" : [ "Ercheng Wang", "Huiyong Sun", "Junmei Wang", "Zhe Wang", "Hui Liu", "John Z. H. Zhang", "Tingjun Hou" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "CONTENTS"
    }, {
      "heading" : "1. Introduction A",
      "text" : ""
    }, {
      "heading" : "2. Methodology C",
      "text" : ""
    }, {
      "heading" : "3. Assessing the Performance of MM/PBSA and MM/GBSA G",
      "text" : ""
    }, {
      "heading" : "4. The Polar Solvation Energy and Entropy Terms in MM/PB(GB)SA Calculations H",
      "text" : "4.1. The Polar Solvation Energy Term in MM/\nPBSA H 4.2. The Polar Energy Solvation Term in MM/\nGBSA I 4.3. Theory, Implementation, and Limitations of\nthe Variable Dielectric Model in MM/GBSA J 4.4. Comparison between PB and GB K 4.5. Efficient Entropy Calculation Methods To\nEstimate the Entropy Change upon Ligand Binding K"
    }, {
      "heading" : "5. The Nonpolar Solvation Energy Term in MM/ PB(GB)SA Calculations L",
      "text" : ""
    }, {
      "heading" : "6. New Toolkits and Web Servers for MM/PB(GB)SA Calculations L",
      "text" : ""
    }, {
      "heading" : "7. Applications in Small-Molecule Drug Design M",
      "text" : "7.1. Applications in Virtual Screening M 7.2. Analysis of Critical Interactions for Rational\nDrug Design N"
    }, {
      "heading" : "8. Applications in Macromolecular Interactions O",
      "text" : "8.1. Applications in Protein−Protein Interactions O 8.2. Applications in Protein−Nucleic Acid Inter-\nactions P"
    }, {
      "heading" : "9. QM in MM/PB(GB)SA Calculations Q",
      "text" : ""
    }, {
      "heading" : "10. Comparison with Other Predictive Methods Q",
      "text" : ""
    }, {
      "heading" : "11. Concluding Remarks R",
      "text" : "Author Information S\nCorresponding Authors S ORCID S Author Contributions S Notes S Biographies S\nAcknowledgments S References S"
    }, {
      "heading" : "1. INTRODUCTION",
      "text" : "In thermodynamics, free energy refers to the amount of internal energy of the system that can be used to do work, and it determines the direction of the thermodynamic process as well as the probability that the system will remain in a given\nReceived: January 21, 2019\n© XXXX American Chemical Society A DOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nD ow\nnl oa\nde d\nvi a\nK E\nA N\nU N\nIV o\nn Ju\nly 2\n3, 2\n01 9\nat 1\n8: 04\n:5 0\nSe e\nht tp\ns: //p\nub s.\nac s.\nor g/\nsh ar\nin gg\nui de\nlin es\nf or\no pt\nio ns\no n\nho w\nto le\ngi tim\nat el\nstate. Since the free energy drives all molecular processes, such as protein folding, molecular association, chemical reaction, etc., accurate determination of the free energy is one of the most important tasks in biomolecular studies. At present, molecular dynamics (MD) simulation is the most important tool used to obtain free energies of molecular systems.1 MD simulation not only helps one to understand the physical processes of the system at the atomic level but also enables one to uncover the hidden states of the system that cannot be detected experimentally.2−6 Since experimental measurements of the thermodynamic properties of biomolecular systems are often expensive and time-consuming, accurate theoretical calculations of their free energies by numerical simulation are becoming more and more important in many research fields, such as rational drug design, protein folding, protein−protein interactions (PPIs), etc.1\nIn a real molecular system, such as the binding of a drug to its receptor in a cell, the thermodynamic process is carried out under isothermal−isobaric (NPT) conditions, and the free energy of the system is given by7\nF k T ZlnB= − (1) where kB is Boltzmann’s constant, T is the temperature of the system, and Z is the partition function of the system. Here the system is assumed to be in thermodynamic equilibrium, so the partition function Z can be expressed as7−9\nZ V N h\nPV k T V H k T p r\np r\n1 exp d exp\n( , )\nd d\nN 0 3 B B i k jjjjj y { zzzzz i k jjjjj y { zzzzz∫ ∬= ! − −\n(2)\nwhere V0 is a constant that has units of volume, N is the number of particles in the system, h is Planck’s constant, and P and V are the pressure and volume of the system, respectively. The factor N! in eq 2 appears only for indistinguishable particles. The integration is performed over all phase space (3N positions r and conjugate momenta p). The Hamiltonian H(p, r) is the system’s total energy for a given configuration with known momenta and coordinates. The absolute free energy in eq 1 can be directly computed for a limited number of cases only,1,10,11 for which the systems are usually small, governed by simple Hamiltonians, and analytical expressions for the partition functions exist. For larger systems with complex interactions between particles, it is often impossible to obtain analytical formulas for the partition functions, and thus, their absolute free energies cannot be directly computed using eqs 1 and 2. In most cases, it is often more practical to compute the difference between the free energies of the targeted state and a reference one. Of course, in special cases, if the free energy of the reference state is known, the absolute free energy of the system could still be obtained. For example, an analytical formula for the partition function can be acquired by neglecting the interactions between particles (such as ideal gases) or as a result of the symmetry between the particles (such as ideal crystals). However, most biological events occur in liquid solution, and it is more difficult to define an appropriate reference state for a liquidphase system than those ideal systems. Therefore, in areas such as drug design,12−15 protein−protein/ligand interactions,16,17 solubility of small molecules,18,19 protein−ligand binding affinities,20−24 protein folding,25,26 and conformational changes of biological macromolecules,27 it is more convenient and realistic to calculate the free energy difference for an event or\nthe relative free energy of two states. In general, combining the statistical mechanical expressions for F to estimate ΔFBA, the free energy difference between two (or possibly a series of) states A and B, gives28\nF F F k T k T p\np ln Z Z lnBA B A B B\nA B\nB\nA\nΔ = − = − = − (3)\nwhere pA and pB are the probabilities that the system is state A or B, respectively. In drug design, the binding free energy is often used to characterize the binding strength between a receptor and a drug molecule. The fundamental goal of structure-based drug design is to find new lead compounds that bind as tightly as possible to macromolecular receptors. Compared with the experimental methods, computational methods can significantly reduce the time and cost of designing new drug molecules. Various theoretical methods have been successfully utilized in drug design/discovery.28,29 The proper choice of these methods largely depends on the stage at which the design will be needed, and there is usually a trade-off between the accuracy and efficiency.24\nThe most widely used computational method in structurebased drug design is molecular docking.30−32 The main application of this technique in drug design is to predict the binding poses of candidate compounds in a defined binding pocket and discriminate binders from nonbinders. Although molecular docking is computationally efficient and low-cost, its predictions of binding poses and, particularly, binding free energies as measured by docking scores are usually not of high accuracy,33−36 and it has difficulty in reliably distinguishing compounds with comparable binding affinities. Alchemical free energy (AFE) methods,15,37−39 which are also called pathway methods, require the interconversion of the system from the initial state to the final state via infinitesimal alchemical changes of the energy function, and they are theoretically rigorous and accurate. Free energy perturbation (FEP)40−43 and thermodynamic integration (TI)44−47 are two techniques that are widely utilized in alchemical free energy computations. However, one critical issue of the alchemical methods is the slow convergence of the free energy differences and high computational cost.37 The convergence is particularly difficult in systems involving slow structural transitions or large environmental reorganizations. Hence, these methods are based on Monte Carlo (MC) or MD simulations and require sufficient sampling of complexes, ligands, and intermediate states in solution, resulting in huge computational cost in practical applications. Moreover, the setup of systems for TI and FEP calculations is complicated and requires experience. Recently, software for performing TI and FEP calculations using graphics processing units (GPUs) has begun to emerge.48,49 Even though the computational efficiency is greatly improved in comparison to the CPU versions, TI/ FEP with GPU is still not suitable for large-scale virtual screenings and is mostly used in the stage of lead optimization in a drug design campaign. The above two sets of methods do not perform well in terms of the balance between accuracy and efficiency. On the other hand, end-point free energy methods50−55 have been extensively utilized in structure-based drug design. As the name indicates, end-point methods are based on samplings of the final states of a system, and therefore, they are much less expensive than the pathway methods and more accurate than\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nB\nmost docking scoring functions. The most well known endpoint free energy methods are molecular mechanics Poisson− Boltzmann surface area (MM/PBSA) and molecular mechanics generalized Born surface area (MM/GBSA), developed by Kollman et al.,56−58 which achieve a good balance between computational efficiency and accuracy and thus are the focus of this review. Since the PB solution56,58,59 is computationally time-consuming, a set of more efficient approximation methods based on the GB model59−62 have been developed and have attracted more and more attention.63−67 Another popular method with intermediate performance is linear interaction energy (LIE)55,68−70, whose computational efficiency is second only to that of the scoring function, but we will not discuss it in this review. MM/PBSA and MM/GBSA have been widely used to evaluate docking poses, determine structural stability, and predict binding affinities and hotspots. In addition, MM/PBSA and MM/GBSA allow analysis of the contributions from individual residues or energy terms by free energy decomposition analysis,63,71,72 which gives detailed residue-specific energetic contributions to the system binding, identifies dominant interactions in the binding process, and thereby facilitates individualized drug design. Earlier reviews24,73−76 mainly focused on how to apply MM/\nPBSA and MM/GBSA to calculate binding free energies and how to improve the methods from both the efficiency and accuracy perspectives. Unfortunately, there is not much consensus on these techniques so far, mainly because the computational performance of the methods depends on the system being studied. In this review, we first briefly describe the methodologies of the MM/PBSA and MM/GBSA approaches and then discuss how to improve their performance, with a special emphasis on calculation of the polar solvation energy. Finally, we discuss the latest applications of the MM/GBSA and MM/PBSA methods in the fields of smallmolecule drug design and macromolecule interactions. We hope that the current review will provide readers with helpful guidance in comprehensive understanding of the methodologies as well as practical applications of the MM/GBSA and MM/PBSA approaches."
    }, {
      "heading" : "2. METHODOLOGY",
      "text" : "In the MM/PBSA or MM/GBSA approach, the free energy for binding of the ligand (L) to the protein receptor (R) to form the complex (RL),\nG G G Gbind RL R LΔ = − − (4)\ncan be decomposed into contributions of different interactions and expressed as58\nG H T S E G T Sbind MM solΔ = Δ − Δ = Δ + Δ − Δ (5)\nin which\nE E E EMM int ele vdWΔ = Δ + Δ + Δ (6)\nG G Gsol PB/GB SAΔ = Δ + Δ (7)\nG bSASASA γΔ = · + (8)\nwhere ΔEMM, ΔGsol, and −TΔS are the changes in the gasphase molecular mechanics (MM) energy, solvation free energy, and conformational entropy upon ligand binding, respectively. ΔEMM includes the changes in the internal energies ΔEint (bond, angle, and dihedral energies), electrostatic energies ΔEele, and the van der Waals energies ΔEvdW. ΔGsol is the sum of the electrostatic solvation energy ΔGPB/GB (polar contribution) and the nonpolar contribution ΔGSA between the solute and the continuum solvent. The polar contribution is calculated using either the PB or GB model, while the nonpolar energy is usually estimated using the solvent-accessible surface area (SASA).77,78 However, the GB method gives an analytical expression for the polar solvation energy and is thus much faster than the PB method. The change in conformational entropy −TΔS is usually calculated by normal-mode analysis58 on a set of conformational snapshots taken from MD simulations. However, because of the heavy computational cost, changes in the conformational entropy are usually neglected when only the relative binding free energies of similar ligands are needed. The typical steps of using MM/PB(GB)SA combined with MD simulations to calculate the binding free energy include the following: (1) An MD simulation of the protein−ligand complex is performed using an explicit solvent model, as the implicit solvent simulations have been shown to produce less accurate results.79 (2) All of the solvent molecules and charged ions are deleted from each MD snapshot, and the implicit PBSA or GBSA solvent model is used to evaluate the solvation energy. (3) Optionally, the solute conformational entropy change can be computed from a chosen set of snapshots. The final binding free energy is then acquired by a simple summation of these individual energy components. Figure 1 shows the flowchart of the three steps with two computational\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nC\nprotocols (the separate trajectory protocol on the left and the single trajectory protocol on the right). It is noted that the reason for applying an implicit solvation model to calculate the free energy of a system is to avoid the large fluctuation of potential energies when explicit water molecules are used in the calculation.80 However, the above computational protocol of applying both the explicit and implicit solvation models in the first two steps is arguably inconsistent, as the MD simulation and energy calculation share the inconsistent energy functions, thus requiring reweighting of some energy terms. Although one could in principle avoid this inconsistency by also performing the MD simulation with an implicit solvent model, the result of such an approach is generally less reliable, and the simulation may even lead to dissociation of a ligand from its receptor or a protein subunit from the others.79 Ryde et al. claimed that explicit solvent model for MD simulation is essential and that simulations with implicit water molecules often yield poor results.79 Since water plays an important role in protein−ligand interactions (e.g., water molecules can form hydrogen bonds between the protein and the ligand), MD simulation in an explicit water solvent system is essential for reliable prediction of the binding free energies of protein− ligand systems. As shown in Figure 1, there are mainly two protocols to generate the conformations in the first step above: (1) performing independent MD simulations for the isolated ligand, apo protein, and bound protein−ligand complex and (2) performing an MD simulation for the bound protein− ligand complex and using a single MD trajectory of the bound complex to obtain the structures of all three components (i.e., the ligand, apo protein and protein−ligand complex).81 In practice, the second protocol is more popular and preferable, and it gives more accurate results with lower standard errors.24 However, the second approach is based on the assumption that the structures sampled for the protein−ligand complex in solution are sufficiently similar to those sampled for the apo protein and the isolated ligand. This assumption is valid in most cases of protein−ligand binding but could be invalid in some cases, e.g., when the protein−ligand binding is associated with large conformational changes.50 A main attractive advantage of the second approach is that the internal energy errors of the systems can be canceled because the energy difference between the protein−ligand complex and its individual components (apo protein and ligand) are computed using exactly identical configurations. However, for the first protocol, the energy difference taken between the averages produced from separate bound and unbound trajectories may result in additional errors or noise due to large internal energy errors at different conformations or structures, and these errors are difficult to eliminate simply by running longer MD simulations. In general, it is a challenge to correctly determine whether the simulation has reached convergence.82 In the second protocol, however, the fluctuations of the energy terms are much smaller because of the cancellation of internal energy errors, but this protocol may suffer from inadequate sampling of the apo receptor and/or the ligand. The energy terms in eq 5 are averaged over multiple configurations or several MD snapshots (typically a few dozen or hundred structures for ΔEMM and ΔGsol) to improve the predictive accuracy of the binding free energies. Depending on the extent of configurational fluctuations of the system, convergence to the stable states possibly requires relatively longer (multinanosecond) MD simulations. Genheden and\nRyde investigated the convergence issue83 and found that it is better to average the results predicted from several independent MD trajectories, and that opinion is also supported by other works.84−86 For avidin, with a 200 ps production time for each MD run, 5−50 independent MD simulations are needed to reach a statistical accuracy of ∼1 kJ/ mol for the seven biotin analogues.83 Several published works reported that the results of the MM/PB(GB)SA approaches are dependent on the length of the MD simulations.87,88\nJohnson et al. found that with different PB radii, the results of their calculations using the MM/PBSA method based on 0.25−2.00 ns MD trajectories were satisfactory (Pearson correlation coefficient r2 > 0.70),87 but their calculations based on MD trajectories longer than 2 ns gave less accurate results. In a previous work,88 we explored the effect of the length of MD simulations (ranging from 400 to 4800 ps) on binding free energy predictions. The results showed that the length of the MD simulations significantly impacts the accuracy of the predicted binding free energies and that in order to obtain better predictions, longer MD simulations are not necessarily beneficial, with simulation lengths less than 5 ns considered to be reasonable. Virtanen et al., however, concluded that the length of the MD simulations is not of critical importance to the accuracy of the calculations.89 It seems that the impact of the MD simulation length on free energy calculations is system-dependent. A problem with MM/PB(GB)SA is the occurrence of\nseveral substates that are seldom sampled during the simulations. In such a case, a binding free energy with a larger standard error may be obtained beyond expectation,90\nindicating that even longer (maybe >10 ns) or several independent simulations should be performed to yield improved results from a better-equilibrated simulation.83\nRecently, Tsuda et al. proposed a useful machine learning approach (called Best Arm Identify) to optimally regulate the minimum number of MD trajectories for protein−ligand systems.91 Interestingly, an important improvement in MM/ PBSA predictions was also obtained by filtering MD snapshots through prescoring of the protein−ligand complexes with a machine-learning-based approach (SVMSP).92\nAlthough many studies emphasized the importance of MD sampling,93 the minimized conformations could frequently yield predictions as good as or even better than those from MD simulations in practice.94−97 That is to say, MD sampling does not seem to be essential in binding free energy prediction in some cases. Binding free energy can be calculated by MM/ PB(GB)SA on the basis of a single minimized structure rather than abundant MD snapshots. Undoubtedly, that approach costs much less computational time, whereas at the same time it ignores the dynamical effects, resulting in predictions that are extremely dependent on the initial structures and losing all of the information about the statistical accuracy24 of the approach. It seems that the standard deviation in the statistics cannot be utilized to estimate the precision of the predicted binding free energy and various energy terms from multiple MD snapshots. Ryde et al. tested this approach by minimizing selected MD snapshots and showed that the results based on single minimized configurations are similar to those based on MD trajectories but that sometimes unrealistic structures need to be eliminated in order to avoid unpredictable and incorrect binding affinities.79\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nD\nT ab le\n1. A ss es sm\nen ts\nof th e P er fo rm\nan ce\nof th e M M P B SA\nan d M M G B SA\nM et ho\nds si nc e 20 10 a\nsy st em\nm et ho d\nco nt en t\nco nc lu si on s\nye ar\nre f\nsi x pr ot ei n−\nlig an d sy st em\ns M M /P\nB SA\nan d\nM M /G\nB SA\nso lu te\ndi el ec tr ic co ns ta nt ;\nle ng th\nof M D\nsi m ul at io ns ;\nco nf or m at io na le nt ro py\n(1 ) T he\nle ng th\nof th e M D\nsi m ul at io n ob vi ou sl y af fe ct s th e pr ed ic tio\nns of\nbi nd in g fr ee\nen er gi es ,a nd\nlo ng er\nsi m ul at io ns\nar e no t\nal w ay s ne ce ss ar y to\nac hi ev e be tt er\npr ed ic tio\nns .\n20 11\n88\n(2 ) T he\npr ed ic tio\nns ba se d on\ndi ffe re nt\nso lu te\ndi el ec tr ic co ns ta nt s ar e qu ite\ndi ffe re nt .\n(3 ) La rg e flu ct ua tio\nns of\nco nf or m at io na le nt ro py\nof te n ap pe ar in M D tr aj ec to ri es ,a nd\na la rg e nu m be r of\nsn ap sh ot s ar e ne ce ss ar y to\nob ta in\nst ab le pr ed ic tio\nns .\n(4 ) M M /P\nB SA\nex hi bi ts be tt er pe rf or m an ce\nth an\nM M /G\nB SA\nin pr ed ic tin\ng ab so lu te bi nd in g fr ee\nen er gi es ,b ut\nit m ay\nbe no ta\nbe tt er\nch oi ce\nto ca lc ul at e re la tiv e bi nd in g fr ee\nen er gi es .\n98 pr ot ei n−\nlig an d co m pl ex es\nM M /P\nB SA\nan d\nM M /G\nB SA\nM D\nsa m pl in g;\npe rf or m an ce\nof M M /P\nB SA\nan d M M /\nG B SA\n(1 ) M M /G\nB SA\nou tp er fo rm\ns M M /P\nB SA\nan d m os t po pu la r sc or in g fu nc tio\nns in\nid en tif yi ng\nth e co rr ec t bi nd in g co nf or m at io n.\n20 11\n93\n(2 ) M D\nsi m ul at io n is es se nt ia l to\nco rr ec tly\nid en tif y th e bi nd in g st ru ct ur es\nfo r so m e sy st em\ns.\n(3 ) M M /G\nB SA\nsh ow\ns go od\npe rf or m an ce\nin pr ed ic tin\ng bo th\nbi nd in g po se s an d bi nd in g fr ee\nen er gi es .\nfo ur\npr ot ei n−\nlig an d sy st em\ns M M /G\nB SA\ndi ffe re nt\nin iti al iz at io n\n(1 ) T he\npr ed ic tio\nns of\nM M /G\nB SA\nba se d ev en\non st ru ct ur es\nge ne ra te d by\ndi ffe re nt\nM D\nsi m ul at io n pa ck ag es\nar e re as on ab ly\nre pr od uc ib le .\n20 11\n10 3\n(2 ) So lv at in g th e sy st em\ns w ith\ndi ffe re nt\neq ui lib ra te d w at er\nbo xe s ca n al so\nsa m pl e ex te ns iv e co nf or m at io ns ,i n ad di tio\nn to\nth e\nco m m on\nus e of\ndi ffe re nt\nin iti al ve lo ci tie s.\nse ve n bi ot in\nan al og ue s bi nd in g to\nav id in\nan d ni ne\nin hi bi to rs bi nd in g to\nfa ct or\nX a (f X a)\nM M /P\nB SA\nan d\nM M /G\nB SA\nso lu te\ndi el ec tr ic co ns ta nt ;\nel ec tr os ta tic\nco nt ri bu tio\nns (1 ) T he\npr ed ic te d ac cu ra cy\nof th e tw o ap pr oa ch es\n(3 A -M\nM /G\nB SA\nan d 1A\n-M M /G\nB SA\n) de pe nd s on\nth e te st ed\nca se\nan d th e\nso lv at io n m od el .\n20 12\n51\n(2 ) C om\nbi ni ng\nM M /P\nB (G\nB )β\nw ith\nth e st ri ct er\nLR A ap pr oa ch\nyi el ds\nth e be st pr ed ic tio\nns fo r av id in ,w\nhe re as\nth e pu re\nM M /P B (G B )S A ap pr oa ch es yi el d th e be st pr ed ic tio ns fo r fX a.\n(3 ) T he\npr ec is io n ca n be\nim pr ov ed\nw ith\na re la tiv el y hi gh er\ndi el ec tr ic co ns ta nt ,e sp ec ia lly\nfo r th e 3A\n-M M /P\nB β m et ho d.\n(4 ) T he\nop tim\num so lu te\ndi el ec tr ic co ns ta nt\nfo r PB\nis sl ig ht ly hi gh er\nth an\nth at\nfo r G B .\nei gh t in hi bi to rs\nbi nd in g to\nfX a, ni ne\nin hi bi to rs bi nd in g to\nfe rr iti n, an d tw o\nlig an ds\nbi nd in g to\nH IV -1\npr ot ea se\nM M /G\nB SA\nsy st em\ntr un ca tio\nn; bu ffe r\nre gi on ; so lu te\ndi el ec tr ic\nco ns ta nt\n(1 ) T ru nc at io n of\nth e pr ot ei n is no t in no ce nt .H\now ev er ,i t al m os t al w ay s im pr ov es\nth e pr ed ic te d pr ec is io n fo r th e tr un ca te d\nsy st em\ns. 20 12\n10 4\n(2 ) T he\npr ed ic tio\nns w ith\na di st an ce -b as ed\ndi el ec tr ic co ns ta nt\ngi ve\na ra th er\nco ns ta nt\nM A D .\n(3 ) A sh el l of\nfix ed\nw at er\nm ol ec ul es\nan d pr ot ei n re si du es\nis cr uc ia l in\nst ab ili zi ng\nth e en er gi es\nfo r th e tr un ca te d sy st em\ns.\n(4 ) O m itt in g th e en tr op y ef fe ct is no ta lw ay s ap pr op ri at e. C al cu la tin\ng en tr op ie s us in g a pr ot ei n tr un ca te d be yo nd\na di st an ce\nof 8 Å\nfr om\nth e lig an d w ith\na 4 Å bu ffe r of\nfix ed\npr ot ei n re si du es\nan d w at er\nm ol ec ul es\nto ge th er\nw ith\na di el ec tr ic co ns ta nt\nof 1 gi ve s a\ngo od\nba la nc e be tw ee n ac cu ra cy\nan d co m pu ta tio\nna l ef fic ie nc y, on ly fo r pr ed ic tin\ng th e re la tiv e bi nd in g af fin iti es .\n46 sm\nal l m ol ec ul es\nbi nd in g to\nfiv e\npr ot ei ns\nM M /P\nB SA\nan d\nM M /G\nB SA\nfo rc e fie ld s; lig an d ch ar ge m od el s\n(1 ) Fo\nr sh or t M D\nsi m ul at io ns\n(< 1 ns ), ff0 3 yi el ds\nth e be st pr ed ic tio\nns us in g bo th\nM M /G\nB SA\nan d M M /P\nB SA\n.F or\nm ed iu m\nM D\nsi m ul at io ns\n(2 − 4 ns ), M M /G\nB SA\nw ith\nff9 9 yi el ds\nth e be st pr ed ic tio\nns ,w\nhi le M M /P\nB SA\nw ith\nff9 9S B pe rf or m s th e be st .L\non ge r\nsi m ul at io ns\n(> 5 ns ) m ay\nno t be\nqu ite\nne ce ss ar y.\n20 13\n97\n(2 ) M M /P\nB SA\nw ith\nT an ’s pa ra m et er s ov er co m es\nM M /G\nB SA\n(G B O B C 1 )\nin te rm\ns of\nra nk in g ab ili ty .\n(3 ) R ES\nP ch ar ge s yi el d th e op tim\nal pe rf or m an ce\nfo r M M /P\nB SA\nan d M M /G\nB SA\n,a nd\nth e re su lts\nba se d on\nA M 1- B C C\nan d ES P ch ar ge s ar e al so fa ir ly sa tis fa ct or y.\nfiv e lig an ds\nbi nd in g to\nga l3\nM M /G\nB SA\nM D\nw ith\nex pl ic it an d im -\npl ic it so lv en t\n(1 ) T he\npr ed ic te d ac cu ra cy\nan d pr ec is io n ar e ex tr em\nel y in flu en ce d by\nth e ch oi ce\nof so lv en tm\nod el bo th\nin th e M D si m ul at io ns\nan d\nin th e en er gy\nca lc ul at io ns .\n20 13\n10 5\n(2 ) R M SD\nan al ys is co ul d ha rd ly di st in gu is h th e ge ne ra te d en se m bl es .\n(3 ) M M /G\nB SA\nba se d on\nm in im iz at io ns\nm ay\nno ty ie ld re su lts\nsi m ila r to\nth os e fr om\nst an da rd\nM M /G\nB SA\nba se d on\nM D si m ul at io ns .\nT he\npr ed ic tio\nns ba se d on\nm in im iz at io ns\nsh ow\nw or se\nco nv er ge nc e.\n18 72\npr ot ei n−\nlig an d co m pl ex es\nM M /P\nB SA\nan d\nM M /G\nB SA\nsi m ul at io n pr ot oc ol s; so lu te di el ec tr ic co ns ta nt\n(1 ) B ot h M M /G\nB SA\nan d M M /P\nB SA\nca lc ul at io ns\nba se d on\na di el ec tr ic co ns ta nt\nof 4 sh ow\nth e be st un bi as ed\nac cu ra ci es\n(t he\non e-\npr ot ei nfa m ily /o ne -b in di ng -li ga nd\nca se ) an d th e be st ov er al la cc ur ac ie s (b as ed\non th e 18 64\npr ot ei n−\nlig an d co m pl ex es ) fo r M M /\nG B SA\npr ed ic tio\nns .\n20 14\n98\n(2 ) T he\nac cu ra ci es\nof bo th\nth e M M /G\nB SA\nan d M M /P\nB SA\npr ed ic tio\nns de cr ea se\nw ith\nin cr ea si ng\nlig an d to ta l fo rm\nal ch ar ge .\n(3 ) M M /P\nB SA\nw ith\nhi gh er sy st em\nat ic se ns iti vi ty is po te nt ia lly\nm or e su ita bl e fo r in di vi du al -t ar ge tle ve lp re di ct io n th an\nM M /G\nB SA\n.\nth re e ty ro si ne\nki na se s (A\nB L,\nA LK\n,a nd\nB R A F)\nM M /P\nB SA\n,M M /\nG B SA\n,a nd\ndo ck -\nin g\nso lu te\ndi el ec tr ic co ns ta nt\n(1 ) A hi gh er\nso lu te di el ec tr ic co ns ta nt\n(ε = 2 or\n4) is pr ef er re d to\nim pr ov e th e re sc or in g ac cu ra cy\nfo r bo th\nM M /G\nB SA\nan d M M /\nPB SA\n. 20 14\n94\n(2 ) M D\nsi m ul at io ns\nm ay\nbe un ne ce ss ar y to\nim pr ov e en ri ch m en t, bu t op tim\niz at io ns\nar e in de ed\nne ce ss ar y fo r M M /G\nB SA\nor M M /\nPB SA\nre sc or in g.\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nE\nT ab le\n1. co nt in ue d sy st em\nm et ho d\nco nt en t\nco nc lu si on s\nye ar\nre f\n16 in hi bi to rs bi nd in g to\nFa bI\nM M /P\nB SA\n,M M /\nG B SA\n,a nd Q M − M M /G\nB SA\nra di i se ts ; G B m od el s; en - tr op y; Q M m et ho ds ; M D sa m pl in g\n(1 ) M M /P\nB SA\nre su lts\nba se d on\n0. 25\nto 2. 00\nns M D tr aj ec to ri es\nw er e sa tis fa ct or y in\nal lb on di ,m\nbo nd i, m bo nd i2 ,a nd\nPA R SE\nra di i\nse ts .H\now ev er ,u si ng\n≥ 2 ns\nM D tr aj ec to ri es\nfo r M M /P\nB SA\nse em\ned to\nlo w er th e ac cu ra cy\nof pr ed ic tio\nn w ith\nal lf ou r ra di is et s. Fo r M M /G B SA ,t he cr iti ca l M D le ng th is 1 ns .\n20 15\n87\n(2 ) It w as cl ea rly\nse en\nth at bo nd ia nd\nm bo nd i2 ga ve\nal m os ti de nt ic al pr ed ic tiv e po w er .M\nM /G\nB SA\nis m or e se ns iti ve\nto va ri ou s ra di i\nse ts th an\nM M /P\nB SA\n,a nd\nth e m bo nd i ra di i se t w as\na no nr ec om\nm en de d ra di i se tt in g fo r G B O B C .\n(3 ) G B H C T of fe re d th e be st ag re em\nen t w ith\nth e ex pe ri m en ta l bi nd in g re su lts .\n(4 ) M M /G\nB SA\nan d Q M − M M /G\nB SA\npr ov id e be tt er\nac cu ra cy\nan d hi gh er\nef fic ie nc y th an\nM M /P\nB SA\nus in g ei th er\nth e m ul tip le in de pe nd en t sa m pl in g m et ho d or th e tr ad iti on al si ng le lo ng si m ul at io n m et ho d.\n46 pr ot ei n−\npr ot ei n co m pl ex es\nM M /P\nB SA\nan d\nM M /G\nB SA\nfo rc e fie ld s; so lu te\ndi el ec tr ic\nco ns ta nt ; G B m od el s\n(1 ) T he\nM M /G\nB SA\nca lc ul at io ns\nyi el d th e be st r P\nof − 0. 64 7,\nw hi ch\nis be tt er\nth an\nth at\nfo r M M /P\nB SA\n. 20 16\n93\n(2 ) T he\nre sc or in g ac cu ra cy\nfo r M M /G\nB SA\nis im pr ov ed\nw ith\na lo w er\nso lu te\ndi el ec tr ic co ns ta nt .\n(3 ) T he\nPB A of\nth e bi nd in g in te rf ac e of\na pr ot ei n−\npr ot ei n co m pl ex\nca n po ss ib ly be\nap pl ie d as\na cr ite ri on\nto ch oo se\nth e op tim al so lu te di el ec tr ic co ns ta nt in M M /G B SA ca lc ul at io ns to re co gn iz e th e co rr ec t bi nd in g po se s.\n20 in hi bi to rs bi nd in g to\nPL K 1\ndo ck in g, FE P, M M /G B SA\n,a nd\nQ M − M M /G\nB SA\nle ng th\nof M D\nsi m ul at io ns ; ra di i se ts ; G B m od el s; m ul tip le sh or t M D si m ula tio ns\n(1 ) Fo\nr M M /P\nB SA\n,e ve n 10\nns is no te no ug h to\nge tt he\nop tim\nal r S ,w\nhi le fo r M M /G\nB SA\n,8 ns\nse em\ns to\nbe a pl au si bl e ch oi ce\nto ge t\nth e id ea l re su lt.\n20 17\n10 6\n(2 ) T he\nra nk in g ca pa bi lit y of\nFE P is th e be st .\n(3 ) T he\nr S ob ta in ed\nfr om\nth e 8 ns\nM D sa m pl in gba se d M M /G\nB SA\nsc or e ca n re ac h 0. 76 7, w hi ch\nis lo w er th an\nth at of FE\nP by\n0. 08 7,\nbu t its\nco m pu ta tio\nna l co st is m uc h le ss\nth an\nth at\nof FE\nP.\n(4 ) T he\nra nk in g pe rf or m an ce\nof M M /G\nB SA\nca n be\nob vi ou sl y im pr ov ed\nby tr ea tin\ng th e lig an ds\nw ith\na Q M\nm et ho d.\n(5 ) m bo nd i is m or e se ns iti ve\nto th e G B m et ho d,\nan d th e re co m m en de d va lu e of\nig b is 5.\n(6 ) A m on g th e th re e ki nd s of\ntr ad iti on al do ck in g sc or in g fu nc tio\nns ,t he\nra nk in g pe rf or m an ce\nof a fo rc efie ld -b as ed\nsc or in g fu nc tio n is m uc h be tt er fo r co ng en er ic co m po un ds .\nR SL\nle ct in\nbo un d to\nM eF uc\nM M /P\nB SA\n,M M /\nG B SA\n,a nd\nQ M −\nM M /G\nB SA\nG B m od el s; Q M\nm et ho ds ;\nen tr op ic co nt ri bu tio\nns (1 ) T he\nbi nd in g fr ee\nen er gi es\nus in g im pl ic it so lv en t m et ho ds\nar e se ns iti ve\nto th e si m ul at io n le ng th ,r ad ii se t, G B m od el ,a nd\nQ M\nH am\nilt on ia n.\n20 18\n10 7\n(2 ) T he\nM M /P\nB SA\nan d M M /G\nB SA\nca lc ul at io ns\nfr om\na 7 ns\nM D\nsi m ul at io n pr ov id ed\nst at is tic al ly\ngo od\nag re em\nen t w ith\nth e\nex pe ri m en ta l bi nd in g af fin iti es . (3 ) M M /P B SA\nus in g th e m bo nd i ra di i se ts of fe rs th e be st co rr el at io n.\n(4 ) O ut\nof 12\nQ M\nH am\nilt on ia ns\nte st ed ,P\nM 6,\nD FT\nB ,a nd\nth ei r va ri an ts pr ov ed\nto be\nm or e ef fic ie nt\nth an\not he r se m ie m pi ri ca l\nm et ho ds .\n(5 ) T he\nin cl us io n of\nen tr op ic te rm\ns m ay\nbe re as on ab le on ly w he n ai m in g to\nob ta in\na qu an tit at iv el y be tt er\nag re em\nen t w ith\nex pe ri m en ta l va lu es .\n15 08\npr ot ei n−\nlig an d co m pl ex es\nM M /P\nB SA\nan d\nM M /G\nB SA\nfo rc e fie ld s; so lu te\ndi el ec tr ic co ns ta nt ; en tr op y ef fe ct s\n(1 ) T he\nff0 3 fo rc e fie ld\nal w ay s pe rf or m s th e be st ac ro ss\nal l si x te st ed\nfo rc e fie ld s fo r ea ch\nca lc ul at io n st ra te gy\nat an y di el ec tr ic\nco ns ta nt .\n20 18\n99\n(2 ) O ne\nsh ou ld\nbe ca ut io us\nto es tim\nat e lig an dbi nd in g fr ee\nen er gi es\nw ith\nN M A w he n us in g m in im iz ed\nst ru ct ur es .\n(3 ) T he\nin cl us io n of\ntr un ca te d N M A en tr op ie s ca n im pr ov e th e pe rf or m an ce\nof bo th\nM M /G\nB SA\nan d M M /P\nB SA\nre su lts\nat a\nre la tiv el y hi gh\ndi el ec tr ic co ns ta nt\n(ε = 4) .\n14 8 pr ot ei n−\nR N A co m pl ex es\nM M /P\nB SA\n,M M /\nG B SA\n,a nd\ndo ck -\nin g\nso lu te\ndi el ec tr ic co ns ta nt ;\nG B m od el s\n(1 ) T he\nbe st pr ed ic tio\nn co m es\nfr om\nM M /G\nB SA\nca lc ul at ed\nus in g th e G B G B n1 m od el w ith\na di el ec tr ic co ns ta nt\nof 8 ba se d on\n1 ns\nM D\nsi m ul at io ns\nin T IP 3P\nw at er\nso lv en t.\n20 18\n10 0\n(2 ) T he\nco m pu ta tio\nna l pr ot oc ol\nof si m pl e m in im iz at io n of\nbi nd in g po se s in\nex pl ic it so lv en t us in g th e ff1 4S B fo rc e fie ld\nan d\nca lc ul at io n of\nth e bi nd in g fr ee\nen er gi es\nus in g th e G B G B n1 m od el w ith\na di el ec tr ic co ns ta nt\nof 2 yi el ds\nth e sa tis fie d co rr el at io n.\n(3 ) M M /G\nB SA\nis a po w er fu l sc or in g fu nc tio\nn fo r pr ot ei n−\nR N A do ck in g st ud ie s.\na A bb re vi at io ns : LR\nA ,l in ea rre sp on se\nap pr ox im at io n;\nM A D ,m\nea n ab so lu te\nde vi at io n;\nQ M ,q\nua nt um\nm ec ha ni cs ; r P ,P\nea rs on\nco rr el at io n co effi\nci en t; PB\nA ,p\nol ar\nbu ri ed\nar ea ; r S ,S\npe ar m an\nco rr el at io n\nco effi\nci en t; PM\n6, pa ra m et ri ze d m od el nu m be r 6;\nD FT\nB ,d\nen si ty\nfu nc tio\nna l th eo ry -b as ed\ntig ht\nbi nd in g;\nN M A ,n\nor m al -m\nod e an al ys is ; R M SD\n,r oo tm ea nsq ua re\nde vi at io n.\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nF"
    }, {
      "heading" : "3. ASSESSING THE PERFORMANCE OF MM/PBSA AND MM/GBSA",
      "text" : "In a series of published works, we have systematically evaluated the prediction capability of the MM/PBSA and MM/GBSA methods.88,93,94,97−101 The results suggest that the prediction of binding free energy strongly depends on the force field,79,97 charge model,97 continuum solvation method,102 interior dielectric constant,94 sampling method,79 and conformational entropy.99 In Table 1, we summarize some benchmark reports assessing the performance of the MMPBSA and MMGBSA methods since 2011. The general conclusions include the following: (1) 1 ns MD simulation in explicit solvent with the AMBER ff03 force field is critical for the MM/GBSA calculation; (2) a relatively higher solute dielectric constant (εin = 2 or 4) is preferable to improve the rescoring accuracy of MM/PB(GB)SA; (3) MM/PBSA is more sensitive to the investigated systems than MM/GBSA; (4) the Hawkins− Cramer−Truhlar GB model (GBHCT) gives the best agreement with the experimental values of binding affinities, and the mbondi radii set is not recommended for the Onufriev− Bashford−Case GB model (GBOBC). The force field plays a central role in molecular simulations since it determines all of the interactions of a system.108 Ryde et al. studied the effects of the force field on the predicted ligand binding affinities calculated by MM/PBSA using three different versions of the nonpolarizable AMBER force field (AMBER ff94, ff99, and ff03) and obtained similar results.79 Better force fields such as polarizable force fields are desirable for use in MM/PBSA, as the current implicit solvent models were developed for nonpolarizable force fields. In our previous work, 46 small molecules targeting five different protein targets were used to test the effects of five AMBER force fields and four different charge models.97 We reached the following conclusions: (1) for short MD simulations (<1 ns), the AMBER ff03 force field yields the optimal prediction by both MM/GBSA and MM/PBSA; (2) for medium-length MD simulations (2−4 ns), MM/GBSA with ff99 and MM/PBSA with ff99SB give the optimal predicted results. It should be noted that these conclusions are restricted to the set of force fields used in that study (AMBER ff99, ff99SB, ff99SB-ILDN, ff03, and ff12SB). These results indicate that the force field used in MD simulations and MM/PB(GB)SA calculations should be consistent and that mixing of different force fields may cause inaccurate predictions. Gohlke and Case studied in detail how the results of binding free energy prediction depend on the polar solvation energy.66 The results suggested that the PB predictions were largely impacted by the radii used, as the multiple variants of GB radii gave very different results. Among the four radii sets studied (bondi, mbondi, mbondi2, and PARSE), the results obtained using PARSE showed the lowest correlation with the experimental data (r2 = 0.62−0.77), and unexpectedly, the difference between the predictions based on mbondi and mbondi2 was very small.87 Recently, Ryde et al. proposed a method called MM/3D-RISM and compared the predictions of the new method with those of four GB and two PB methods.102 Their results indicated that the accuracy of the MM/3D-RISM approach (Pearson correlation coefficient rP = 0.90) was comparable to that of the best MM/PBSA method (rP = 0.93), but the mean absolute deviation (MAD) was significantly worse (37 kJ/mol compared with 16 kJ/mol). Comparison of the MM/3D-RISM and MM/PBSA ap-\nproaches was also made by Pandey et al., and in general, MM/PBSA performed better than MM/3D-RISM in the predictions of the relative binding free energies for three protein systems.109 We evaluated the accuracy of the MM/ GBSA predictions of three GB models,88 and the results showed that the GB model developed by Onufriev, Bashford, and Case110 is the best one for ranking the binding affinities of the inhibitors. In most cases, the MM/PBSA calculation with Tan’s PB parameters shows better ranking performance than MM/GBSA (GBOBC1). Restrained electrostatic potential (RESP) charges yield the optimal capability for MM/PBSA and MM/GBSA, while the predictions based on the AM1-BCC and ESP charges are also fairly satisfactory. Johnson et al. found that the use of multiple short MD trajectories did not decrease the MM/PB(GB)SA performance compared with a single long MD simulation trajectory,87 indicating that multiple independent dynamic samplings can offset the errors due to the force field. Therefore, the use of multiple independent samplings is recommended, which tends to average out the difference between different GB methods. In addition, we also assessed the performance of MM/GBSA and MM/PBSA in reproducing the absolute binding free energies for a large data set.88,99 The results showed that MM/ GBSA gives worse predictions than MM/PBSA in calculating the absolute binding free energies. However, MM/GBSA produces better performance in ranking the binding affinities for systems without metals. Thus, MM/GBSA, with its much better computational efficiency, can be a powerful tool in drug design, where researchers frequently pay attention to the rational ranking of inhibitors. Although MM/GBSA and MM/PBSA are reliable and efficient methods to estimate binding free energies, their weaknesses should also be noticed. In particular, one major source of errors is the conformational entropy. This is often computed by normal-mode analysis (NMA),111−113 which dominates the computational cost of the MM/PB(GB)SA methods. Thus, for structurally similar molecules whose contributions to the conformational entropy are similar, this entropic term is usually ignored, and only the relative binding free energies of those molecules are calculated. Moreover, to decrease the computational cost, Genheden et al.104 and Duan et al.114 developed high-performance entropy calculation algorithms named truncated entropy and interaction entropy, respectively, to estimate the entropy changes for receptor− ligand interactions in MM/PB(GB)SA calculations, and these methods showed improved accuracy in an extensive computational study.99 We developed a very efficient method called weighted solvent-accessible surface area (WSAS) to reproduce the conformational entropies computed by NMA.196 The WSAS method requires no minimization of MD snapshots prior to conformational entropy calculations. It has been successfully used to predict the absolute binding affinities for a variety of systems, including orexin receptor 2115 and cannabinoid receptor 1.116\nBesides the contribution from entropy, the quality of the MM/PB(GB)SA calculations is dependent on the quality of the MD snapshots in representing the entire conformational space sampled as well as several parameters used for the description of the molecular system, such as the force field, the dielectric constants, and the set of atomic radii. Moreover, MM/PBSA and MM/GBSA show some limitations74 in the estimation of binding free energies of highly polar or charged molecules, since the uncertainty in the calculation of the\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nG\nsolvation energy is proportional to the polarity of the considered molecules. Furthermore, contributions of structural water molecules, which bridge the key receptor−ligand interactions, are not taken into account well for predicting the binding free energies by implicit solvation models.117\nPentikaïnen et al.89 investigated the performance of the MM/GBSA, MM/PBSA, and solvation interaction energy (SIE)118,119 approaches in terms of their virtual screening efficiency and ability to predict the binding affinities of five different protein targets. Protein−ligand complexes were prepared by two important methods in structure-based drug design: molecular docking and ligand-based similarity search methods. The results show a significant difference between different binding energy calculation methods. They suggested that these techniques should be used with caution in virtual screening or binding affinity estimation. Moreover, another work assessed the performance of four docking scoring functions and the FEP, MM/GBSA, and QM−MM/GBSA methods on a series of PLK1 inhibitors.106 The ranking performance of FEP is optimal (Spearman correlation coefficient rS = 0.854) and MM/GBSA, which requires much less simulation time (about one-eighth that of FEP), gives a comparable prediction (rS = 0.767). In addition, the ranking performance can be significantly improved by treating the ligands with a quantum mechanics (QM) method. The combination of QM/MM molecular docking120−123 and MM/GBSA calculations has been successfully utilized to reproduce the X-ray geometries of protein−ligand complexes with halogen bonding.124\nBesides, binding free energy prediction is strongly influenced by the solute dielectric constant. Therefore, the energy should be carefully determined on the basis of the characteristics of the protein−protein/ligand binding interfaces. The following section will discuss this issue in detail."
    }, {
      "heading" : "4. THE POLAR SOLVATION ENERGY AND ENTROPY",
      "text" : "TERMS IN MM/PB(GB)SA CALCULATIONS\nMany chemical reactions and biological processes are carried out in solvents, especially in water. Solvation effects are therefore critical to investigate the structures and functions of biological systems such as proteins, DNAs, and RNAs and interactions between them. In the MM/PB(GB)SA methods, the solvation energy is divided into polar and nonpolar contributions. We focus on the polar solvation energy in this section."
    }, {
      "heading" : "4.1. The Polar Solvation Energy Term in MM/PBSA",
      "text" : "The polar solvation term in eq 7 was originally calculated to solve the Poisson−Boltzmann equation (PBE) numerically using a finite difference (FD) solution.125−128 In a biomolecular system with no mobile ions, the Poisson equation is described as129\nr r r( ) ( ) 4 ( )ε φ πρ∇· ∇ = − (9)\nwhere ε(r) is the dielectric distribution function for the solvated molecular system, φ(r) is the electrostatic potential distribution function, and the ρ(r) is the fixed atomic charged density based on the solute atom positions r. However, in most cases of biomolecular systems, because of the presence of salt in the solution, the electrostatic potential φ(r) is obtained by solving the following equation:129\nz ec z e\nk T r r r\nr r( ) ( ) 4 ( ) exp ( ) 4 ( )\ni\nN\ni i i\n1 B\nÄ\nÇ ÅÅÅÅÅÅÅÅÅ\nÉ\nÖ ÑÑÑÑÑÑÑÑÑ ∑ε φ πλ φ πρ∇· ∇ + − = − =\n(10)\nwhere λ(r) is the predefined ion-exclusion function, which has a value of 0 within the Stern layer and the molecular interior and a value of 1 outside the Stern layer, zi is the charge and ci is the bulk number density of ion type i far from the solute at a given temperature T, and e is the electron charge. The summation in eq 10 is over all of the different ion types, and when both the ionic strength and electric field are weak, the nonlinear PBE can be linearized for easier numerical solutions:129\nr r r r( ) ( ) ( ) 4 ( )sol 2ε φ ε κ φ πρ∇· ∇ − = − (11)\nwhere e I k T\n2 8 2\nsol B κ = π\nε is the modified Debye−Hückel parameter, εsol is the solvent dielectric constant, and I is the ionic strength of the solution. The salt term in the PBE can be linearized when the exponent of the Boltzmann factor is close to zero. However, the approximation apparently does not hold in highly charged biomolecular systems.130,131 Thus, it is recommended that a full nonlinear PBE solver should be used for such systems. Obtaining analytical solutions of the linearized and nonlinear PBEs is extremely complicated, even in the few simple cases for which they exist. In the past decades, however, several computational methods have been developed126 to solve the PBE. The classical FD method,127,128 based on the superimposition of a regular rectangular Cartesian mesh over the system where the PBE can be solved, involves the following steps: (1) mapping atomic charges to the FD grid points; (2) assigning nonperiodic/periodic boundary conditions, i.e., electrostatic potentials on the boundary surfaces of the FD grid; (3) applying a dielectric model to define the highdielectric (e.g., water) and low-dielectric (the solute interior) regions and mapping them to the FD grid edges. As a result of the developments in computational algorithms and hardware in recent years, several investigations of the efficiency and accuracy of numerical methods for the linearized equation have appeared,128,132,133 and over the past few years a few new algorithms have been developed for the numerical solution of PBE.134−136 In pbsa137 (a module in the AMBER package,138,139 one of the most popular computer tools to solve PBE), four common linear FD PBE solvers are implemented:140 modified incomplete Cholesky conjugate gradient (ICCG), geometric multigrid, conjugate gradient (CG), and successive over-relaxation (SOR). In addition, six nonlinear FD solvers are implemented:141 inexact Newton (NT)/modified ICCG, NT/geometric multigrid, CG, SOR, and its improved versions, adaptive SOR and damped SOR. The progress made in developing more accurate and efficient solutions to model the electrostatics in biomolecular systems, such as the finite element142−145 and boundary element146−148 methods, was recently reviewed by Alexov et al.126\nThe PBE is mathematically a three-dimensional secondorder nonlinear elliptic partial differential equation. Using FD schemes for solving the PBE, various solvers have been developed, including PBSA,137 MIBPB,149 DelPhi,150 UHBD,151 ZAP,152 and many others. The ZAP algorithm, developed by Nicholls et al., was incorporated into the CHARMM153 package, providing a fast, stable, smooth permittivity model for implicit solvation energy calculations.154\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nH\nUnfortunately, many popular PB methods do not converge. Specifically, their solution changes dramatically when the grid mesh is refined. This happens because of the discontinuous dielectric constants used across the solvent−solute interface.155 To our knowledge, the only existing second-order convergent PB method for realistic protein surfaces is the MIBPB approach (https://weilab.math.msu.edu/MIBPB/). That is, the accuracy increases 4 times when the grid mesh size is halved.149 In MIBPB, the grid mesh size should be set in the range of 0.2 to 1.2 Å, and a default value of 0.8 Å is used if the size is not specified. The convergence of MIBPB for protein− ligand binding analysis has been carefully tested recently, showing a relative error of 0.4%.156\nAlthough numerical algorithms have been implemented to solve the PBE, currently all serial PBE solvers on CPUs are capable of calculating the electrostatics of only relatively small biomolecules and systems because of the intensive demand of computational resources (both time and memory) required to calculate the electrostatics of large systems (such as biomolecules and the complexes between them).157−159 To obtain accurate results for large systems, even the fastest solvers, such as the DelPhi program,150 typically take more than half a day to perform the calculations at the minimum requirement of grid resolution. Such computational efficiency is insufficient to meet current researchers’ requirements in practical applications. Therefore, significant acceleration is required to make these serial algorithms suitable for studying large systems. In addition to developing new algorithms, there are two ways to speed up the current PBE solvers: (1) soft acceleration, that is, running parallel solvers on multiple CPUs, and (2) GPU acceleration. Several popular PBE solvers have been parallelized via different techniques to allow users to perform intensive calculations on parallel computers/clusters, such as pbsa,137,160 APBS,161 and DelPhi.159 Solving the PBE on CUDA-based GPUs is much more efficient.157,158,162 A FD scheme with the successive over-relaxation approach in the DelPhi package was implemented on NVIDIA GPUs, achieving a speedup of ∼10 times in both the linearized and nonlinear cases.157 In the AMBER 2018 release, two new solvers were added to use NVIDIA GPUs to accelerate the FD PB calculations.158 The GPU version of pbsa is called pbsa.cuda. It should be pointed out that only the numerical solvers are ported to the GPU platforms, while the other pbsa system building routines remain unchanged. A fully GPUenabled pbsa and associated MM/PBSA functions are still under development. More details on the GPU version of pbsa are provided in the AMBER 2018 reference manual.139\nThe advantage of the PBE is that the water in the solution is reduced to a dielectric medium with a uniform dielectric constant. This treatment of the solvent greatly simplifies simulations of biomacromolecules. However, the disadvantage of implicit solvent is the use of the mean-field approximation. When a certain concentration of high-valent ions in the aqueous solution leads to ionic interactions and correlation enhancement, the PBE cannot accurately describe those kinds of systems.130,131"
    }, {
      "heading" : "4.2. The Polar Energy Solvation Term in MM/GBSA",
      "text" : "In MD applications, the associated computational costs are often very high, as the PBE needs to be solved every time the conformation of a molecule changes. To solve the problem, the GB model, a faster and more efficient approximation of PBE, has been developed. In a GB model, atoms are described as\ncharged spheres whose internal dielectric constant is lower than that of the environment.163,164 The screening that each atom experiences is determined by the local environment. The more an atom is surrounded by other atoms, the less its electrostatics will be screened since it is surrounded by lowerdielectric material. This property is called descreening of one atom by another. Different GB models calculate atomic descreening differently. Descreening is used to calculate the Born radius of each atom, and thus, the Born radius of an atom describes the degree of descreening. A large Born radius represents small screening (strong electric field), as if the atom is in vacuum. A small Born radius represents large screening (weak electric field), as if the atom is in bulk water. The canonical GB equation165 with the absence of salt can be written as166\nG q q\nf 1 1\ni j\ni j GB\nin sol , GB i k jjjjj y { zzzzz∑ε εΔ = − − (12)\nin which\nf r r\nexp 4ij ij\nij\nij GB\n2 2 2\n2\ni\nk\njjjjjj y\n{ zzzzzzα α= + (13) where rij is the distance between atoms i and j, qi and qj are the partial charges of those atoms, and αij is the geometric average of the efficient Born radii αj and αj. It is assumed that the atom is uniformly filled with a material with a low dielectric constant (εin = 1) and the molecule is surrounded by a solvent with a high dielectric constant (εsol = 80 for water at 300 K). Case et al. also derived an extension of the basic GB model that allows for the treatment of mobile ions167 by modification of eq 12 to\nG f q q f 1 exp( )\ni j\ni j GB\nin\nGB\nsol , GB\nÄ\nÇ ÅÅÅÅÅÅÅÅÅÅ\nÉ\nÖ ÑÑÑÑÑÑÑÑÑÑ ∑ ε κ ε Δ = − − −\n(14)\nFrom the GB equation, it can be seen that the GB calculation is strongly dependent on the efficient Born radii. The first GB model implemented in the AMBER software package, which is called the GBHCT model (igb = 1), was developed by Hawkins, Cramer, and Truhlar168,169 with the parameters described by Tsui and Case.170 Another widely used GB model, GBOBC, was developed by Onufriev, Bashford, and Case62,110 (igb = 2 or 5 in AMBER). In this model, the effective Born radii are readjusted to account for the interstitial spaces between atom spheres missed by the GBHCT approximation. As such, GBOBC has a closer approximation to true molecular volume than GBHCT, albeit in an average sense. The GBn models (igb = 7 or 8 in AMBER) yield results in considerably better agreement with PB and explicit solvent than the GBOBC models on molecular surfaces of MD snapshots under numerous circumstances.171 The GBn model, parametrized for peptides and proteins, is not recommended for nucleic acids. The GB models have also been implemented in CHARMM,153 referring to the works reported by Brooks et al.163,172\nMore recently, Onufriev et al. presented a grid-based surface implementation of the “R6” integration173,174 of the GB model, named GBNSR6,175 in which the effective Born radii were calculated numerically. The model can be described as\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nI\nR r r\nr r S 1 4 di V i\ni\n3 6∮π= − − | − | ·− ∂ (15)\nwhere ∂V represents the molecular surface, dS is the infinitesimal surface element vector, and ri and r are the positions of atom i and the infinitesimal surface element, respectively. To reflect the physiological conditions, the ionic strength is set to 0.145 M. The results demonstrate that the accuracy of GBNSR6 with a relatively coarse grid resolution of h = 0.5 Å in computing binding free energies for a set of small protein−ligand complexes remains in the range of kBT ∼ 0.6 kcal/mol, relative to the grid limit (h → 0). Therefore, the default grid resolution of h = 0.5 Å is recommended because the calculations are reasonably fast on a personal computer. Compared with the second-order convergent PB solver (MIBPB149), GBNSR6 gives highly correlated results with r2 = 0.97 and a root-mean-square error of 1.43 kcal/mol. Recent benchmarks show that the electrostatic binding energies computed by GBNSR6 are in good agreement with the numerical PB reference.175,176"
    }, {
      "heading" : "4.3. Theory, Implementation, and Limitations of the Variable Dielectric Model in MM/GBSA",
      "text" : "The continuum model is used to calculate the polar solvation energy of a system by solving the PB or GB equation. In practice, the most common user-tunable parameters for MM/ PB(GB)SA include the solvent and solute dielectric constants. Among them, the solvent dielectric constant εsol represents the nature of the solvent used in the MD simulations (εsol = 80 for water). However, the solute interior dielectric constant εin is especially important in calculating the polar solvation energy, which indirectly affects the accuracy of the binding free energy prediction.177 The solute dielectric constant εin is generally fixed with a value of 1 by default.178 Since ligand−receptor complexes are not continuous uniform dielectric media, the choice of using a single solute dielectric constant is controversial51,88,94,179,180 and could even lead to large errors. In particular, when sorting the ligand−receptor binding free energies, it was observed that the use of εin = 1 resulted in an overestimation of the ligand−receptor electrostatic interaction for some systems.180−183\nSince the atomic charges used to calculate the polar solvation energy have fixed values, they cannot be adapted to respond to the dielectric changes when a solute is solvated in the solvent. Therefore, a charge model that takes the solvent effect into account is critical for the accurate calculation of solvation free energies. Applying a single dielectric constant to describe the heterogeneous dielectric environment of a solute\nmay be problematic. However, for the sake of simplicity, a single dielectric constant is usually used for the whole solute in both the PB and GB models. Instead of using the default dielectric constant, two improved methods have been developed to find the best dielectric constant for a given molecular system that is expected to achieve the best prediction of the polar solvation energy. The first method is based on systematic scanning, in which the solute dielectric constant is scanned from 1 to 25, and the best dielectric constant strongly depends on the characteristics of the whole system.51,88,101,184 The second approach applies variable dielectric constants for different types of residues.179,180 For the first method, several papers have been published that explore the dependence of binding free energy predictions on the solute dielectric constants and suggest that the results are potentially improved by using a larger dielectric constant.74,78,185−187 Genheden and Ryde estimated the optimum dielectric constant and obtained diverse results (εin = 1−25) depending on the solvation model and the tested proteins.51\nSuch results have also been observed in other studies, and although the optimum value of εin is dependent on the characteristics of the binding site (a higher εin for a highly charged binding site and a lower εin for a hydrophobic site),78,88 frequently the calculations are best with εin = 2− 4,94,101,188 especially in larger data sets of diverse proteins.98,184\nThe solvation free energy prediction method based on variable dielectric constant (Figure 2) was first tested by Ravindranathan et al.180 on six pharmaceutically relevant targets, namely, CDK2, fXa, p38_u, PDE10A, human carbonic anhydrase, and p38_pp, in complex with several ligands. They assigned five different εin values (1, 2, 4, 8, and 20) for each type of polar or ionizable residue (Ser, Thr, Asn, Gln, His, Lys, Arg, Asp, or Glu) and assigned the same dielectric constant for the other types of residues. Then, for each system, the best set of dielectric constants evaluated in terms of r2 and predictive index (PI) was selected and discussed. However, this approach results in only a small improvement in the r2 and PI values compared with the standard electrostatic treatment. Especially for the systems whose binding sites composed of nonpolar residues and the ligand−receptor electrostatic interactions are negligible (PDE10A and p38_pp), the predictions are not significantly improved. Mulakala and Viswanadhan189 predicted the binding free energies for two distinct data sets using SGB-NP,190 VSGB-1.0,191 and VSGB-2.0192 (with a variable dielectric model and a novel energy function) and found that the VSGB-2.0 model may approach the accuracy needed for\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nJ\ndetermining the absolute free energy via linear regression without any conformational sampling. The MM/PBSA method of variable dielectric constant has also been used to rank the inhibitory activities of a set of viral inhibitor peptide (VIRIP) mutants that have known IC50 values against HIV-1 gp41 fusion peptide.179 The authors originally assigned the dielectric constant of the wild-type VIRIP−gp41 complex to 2 and set varying dielectric constants for the mutated residues. In contrast to the previously reported scheme, the dielectric constant of each mutated residue was assigned using the following rules: a value of 2 was assigned for the dielectric constant of nonpolar residues, a value of 3 for polar residues, and a value of 4 for charged residues. The authors obtained an improved correlation between the experimental activities and MM/PBSA binding energies compared with that provided by the standard method in which a single dielectric constant of 2 was used for all complexes.179 More recently, Zhang et al. proposed a new strategy by combining the interaction entropy approach recently developed for efficient computing of the entropy change with the use of residue-type-specific dielectric constants in the framework of MM/GBSA, and they obtained optimal results for the predictions of protein−protein binding affinities with optimal εin values of 2.7 for charged residues and 1.1 for noncharged residues (rP = 0.78 and mean absolute error = 2.8 kcal/mol).193\nIn fact, the choice of the solute dielectric constant is strictly system-dependent and requires precise study of the binding sites to obtain the most suitable εin.\n88 The Spearman correlation coefficient rS is often used to assess the correlation between experimental and predicted binding free energies. We systematically studied the effect of the solute dielectric constant on binding free energy calculations for a set of six different protein systems (α-thrombin, avidin, cytochrome c peroxidase, neuraminidase, P450cam, and penicillin).88 Three different dielectric constants, εin = 1, 2, and 4, were evaluated in the PB and GB calculations. We found that the best dielectric constant is system-dependent. For the neuraminidase and α-thrombin systems, which are characterized by highly charged binding sites and the ability to form ion−ion interactions with negatively charged ligands, using εin = 4 is necessary to achieve good correlation for the MM/PBSA calculations (rS = 0.68 and 0.81, respectively). A slightly better result was obtained using the GBHCT model with εin = 4 (rS = 0.78 and 0.90, respectively). MM/GBSA achieved good results for α-thrombin with εin = 2 (rS = 0.88 and 0.91 for GB\nHCT and GBOBC, respectively). Yang et al. obtained consistent results for α-thrombin by applying MM/PB(GB)SA with εin of 1 and 4 to calculate the binding free energies for 28 ligands.184 In this case, εin = 4 gave the best correlation (r\n2 = 0.74 for PB and 0.72 for GB). Additionally, we have carried out related research work on the prediction of binding free energies based on variable dielectric constants and made some progress (data not published). We believe that the application of variable dielectric constants can help to improve the accuracy of binding free energy predictions."
    }, {
      "heading" : "4.4. Comparison between PB and GB",
      "text" : "As mentioned above, the PB calculations are significantly timeconsuming, especially when a finer grid mesh and a larger number of energy calculations are used to achieve better convergence.83,149 Alternatively, the GB method, which is considered as a simple approximation to the PB method,\nrequires much less computer resources than the PB method. For example, we performed a test and found that to perform a complete analysis for an ensemble of 100 snapshots from a constant-temperature MD simulation at 300 K, it takes several minutes to obtain the binding free energy of the popular Ras− Raf system72 using MMPBSA.py194 with a GB model, whereas the computational duration is ∼50 times longer with the PB model. The accuracy of the calculated energy using the GB approach is compromised at the expense of computational speed. However, the correlation and the computational demands make the GB approach attractive, especially for qualitative analysis, though the GB method in principle is not as accurate as PB.178\nMany studies comparing the performance of MM/PBSA and MM/GBSA indicated that the predicted result strongly depends on the system being studied. Ryde et al. predicted the binding free energies of seven biotin analogues and avidin with the MM/PBSA and MM/GBSA methods.79 They found that the GB calculation is much faster than the PB calculation but gives a less accurate result, namely, a MAD of 35 kJ/mol for MM/GBSA compared with 16 kJ/mol for MM/PBSA. Moreover, the estimated ΔGbind values with MM/GBSA are coincidentally lower than the experimental data (by 8−71 kJ/ mol), whereas the results with MM/PBSA are fairly well dispersed around the experimental values (average error = −0.5 kJ/mol). In our previous work, we comprehensively studied how the ranking performance of the binding free energies is influenced by the force field and partial charge model in MM/PBSA and MM/GBSA calculations.97 In most cases, the ranking capability of MM/PBSA with Tan’s parameters is better than that of MM/GBSA (GBOBC1). However, several studies reported that the results predicted by MM/PBSA are worse than those by MM/GBSA.101,195,196 The optimal prediction of MM/GBSA with a solute dielectric constant of 2.0 (rP = 0.66) is better than using MM/PBSA (rP = 0.49) for 98 protein−ligand complexes.101 In addition, the MM/PBSA results are of similar quality,96,98,197 compared with MM/GBSA. Gohlke and Case studied how the predictions depend on the polar solvation energy and suggested that the radii selected in calculations strongly impact the MM/PBSA results. Moreover, different variants of GB models result in different predictions.66"
    }, {
      "heading" : "4.5. Efficient Entropy Calculation Methods To Estimate the Entropy Change upon Ligand Binding",
      "text" : "It is well-known that entropy plays important role in characterizing the absolute binding free energy upon ligand− protein interaction,198−206 but entropy estimation is usually very time-consuming. For example, NMA, which is one of the most widely used entropy estimation methods, needs to expand the covariance matrix of internal coordinates for all of the degrees of freedom and therefore is not suitable for large systems (i.e., systems with protein length >350 residues).198 Meanwhile, many other methods also need very long simulation times to provide convergent predictions of entropy.202,203,206 Consequently, numerous studies simply ignore the entropy term in end-point free energy calculations, which, however, leads to serious overestimation of the predicted binding free energies. Fortunately, several simplified calculation methods have been proposed in recent years, such as the truncated NMA entropy method96 and the interaction entropy method.114 In the truncated NMA entropy method, the protein−ligand complex is truncated into a smaller\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nK\nstructure with the center at the center of mass (CoM) of the ligand, and the residues around the ligand are retained. Usually, the truncation radius is set to 8−16 Å. The truncated structures are subsequently subjected to a traditional NMA calculation. Because of the reduced structures, the NMA calculations require much less time than those for the entire complex structures. We also assessed the performance of the truncated method in reproducing the absolute NMA entropy of the full-length structure, in which the use of a radius cutoff of 9 Å for the truncated structures is sufficient to reproduce the absolute entropies of the full-length structures for most cases.99 Moreover, our additional evaluation on a large data set (PDBbind data set with >1700 structures) also showed that the end-point binding free energy calculations incorporating the truncated NMA entropy can, to some extent, improve the prediction accuracy both in terms of the absolute binding free energies and the correlation with experimental data.99\nThe interaction entropy method is a more recently developed entropy estimation method that considers only the fluctuations of the ligand−receptor interactions during the MD simulations and thus does not need additional computational cost.114 This method has been successfully used in many aspects of molecular interactions such as calculating hot spots for protein−protein interactions,193,207−210 predicting absolute binding free energies for ligand−protein complexes,211−215 etc. In one important work, Aldeghi et al. systemically compared the accuracy of MM/PBSA and the alchemical method (TI)211 and found that incorporation of the interaction entropy into MM/PBSA can significantly improve its performance across all of the tested protocols, indicating that the interaction entropy method is a highly efficient method to improve the performance of the end-point binding free energy calculations. Moreover, we also systemically assessed the performance of the interaction entropy method on the PDBbind data set with >1700 structures for six commonly used AMBER force fields (with 1 ns MD simulation for each system). We found that this approach can significantly improve the overall performance for both MM/GBSA and MM/PBSA in any investigated cases (including different interior dielectric constants, different force fields, etc.) for MD simulations, suggesting that this approach is a very useful tool for entropy estimation."
    }, {
      "heading" : "5. THE NONPOLAR SOLVATION ENERGY TERM IN MM/PB(GB)SA CALCULATIONS",
      "text" : "The nonpolar contribution of the solvation energy results from solute cavity formation within the solvent and van der Waals interactions between the solute and the solvent around the cavity. The nonpolar solvation free energy is typically given by an empirical formula that is proportional to the solvent accessible surface area of the solute:\nG bSASAnp SA γΔ = · + (16)\nwhere γ is the surface tension constant and b is a correction constant (γ = 0.00542 kcal·mol−1·Å−2 and b = 0.92 kcal/mol in the AMBER package). Regardless of the poor accuracy of the SASA model, it has been widely used in the simulations of molecular mechanics and binding affinity predictions. The limitations of this simplified SASA model have been demonstrated previously. The total nonpolar solvation energy, with a small difference between two large components, is independent of the solute surface area or volume but nevertheless is correlated with the repulsive and attractive\ncomponents of the nonpolar contribution computed from the TIP3P simulations.216 To solve that problem, an improved method has been proposed217,218 in which atom-specific surface tension parameters are adopted:\nG SASA i\nN\ni inp SA\n1 ∑ γΔ = · = (17)\nA more modern method in which the nonpolar solvation energy is divided into cavity and dispersion (CD) terms was reported by Luo et al.219 A cavity capable of accommodating the solute in the solvent is created, and then the nonpolar solute is introduced into the cavity. The energy for cavity formation is often estimated using a linear relation to the molecular surface (MS), similar to the SASA model. Hence, the nonpolar solvation energy should be described as\nG b GMSnp CD dispγΔ = · + + Δ (18) A solvent-accessible volume (or surface) integration can be utilized to calculate the dispersion term (ΔGdisp). The scaling factors are typically set to γ = 0.0378 kcal·mol−1·Å−2 and b = −0.569 kcal/mol in the AMBER package. The polarizable continuum model (PCM),220 with separate terms for cavitation, dispersion, and repulsion energies, usually gives more accurate results than SASA. Genheden and Ryde proposed that the nonpolar solvation energy computed by SASA is 3−8 times smaller and of the opposite sign compared with the same energy computed by PCM.24 They studied the binding of benzene to an engineered nonpolar cavity in T4 lysozyme and found that the SASA and CD models yield similar results and that the PCM model is slightly better.221\nAlthough several attempts have been made, none of the above-mentioned methods (namely, the SASA, CD and PCM methods) can yield accurate predictions for systems with more water-exposed binding sites222 because the continuum models ignore all information about water molecules (including the number and entropy changes) before and after ligand binding.24 One approach to solve this problem is to treat the water molecules as a part of the receptor, and improved results have been obtained for some cases;223−225 however, the performance is strongly impacted by the number of explicit water molecules,226 and sometimes this approach yields worse predictions.227 Another way is to replace the desolvation in MM/GBSA by the free energy combined with displacement of binding-site water molecules upon ligand binding estimated by the WaterMap approach, which yields varying results.183,228−230\nUnfortunately, the nonpolar distribution of the solvation free energy has received less attention, to a certain extent because the smaller value of the energy compared with the polar solvation energy. As far as we know, no relevant works on assessment of nonpolar solvation energy predictions have been reported in recent years, and we hope that some will be published in the future because the nonpolar contribution is crucial for obtaining accurate estimates of absolute hydration free energies using implicit solvent models."
    }, {
      "heading" : "6. NEW TOOLKITS AND WEB SERVERS FOR MM/PB(GB)SA CALCULATIONS",
      "text" : "Over the past few years, numerous computational toolkits for MM/PB(GB)SA calculations have been developed and released. MMPBSA.py is a user-friendly Python script implemented in AMBER that automates energy analysis of\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nL\nthe snapshots extracted from an MD trajectory using ideas generated from the continuum solvent models.194 An older Perl script called mm_pbsa.pl has functionality similar to that of MMPBSA.py, but first implicit snapshots (without the water) must be extracted from the production runs for use in the MM/PBSA and MM/GBSA calculations. Free Energy Workflow (FEW) is another set of Perl scripts (including the main script FEW.pl and other Perl modules) developed in AMBER to automate free energy calculations based on TI, MM/PBSA, or LIE.231,232 To integrate high-throughput MD simulations with binding energy calculations, g_mmpbsa was developed as one part of the Open Source Drug Discovery (OSDD) consortium, and it implements the MM/PB(GB)SA approaches using subroutines written in-house or sourced from the GROMACS and APBS packages.233 GMXPBSA is another user-friendly suite of Bash/Perl scripts for streamlining the MM/PBSA calculations on structural ensembles derived from GROMACS trajectories to automatically compute binding free energies for protein−protein or protein−ligand complexes.234 The iAPBS interface written in C/C++/Fortran allows access to the APBS functionality from NAMD.235 This module can be used to perform implicit solvent MD simulations, to write out electrostatic maps for the purpose of visualization, and to perform MM/PBSA calculations directly with NAMD. In addition, the iAPBS interface can serve as the linker between NAMD and other popular software packages like AMBER and GROMACS. FESetup is a tool to automatically set up alchemical free energy simulations for protein−ligand complexes like TI and FEP.236 Postprocessing methods, such as MM/PBSA and LIE, are also supported.236 In a previous work, to facilitate the prediction of binding affinities for protein− protein/ligand systems, we released an easy-to-use pipeline tool named Calculation of Free Energy (CaFE) to perform MM/PBSA and LIE calculations.237 CaFE, powered by the VMD and NAMD programs, is capable of handling numerous static coordinates and MD trajectory file formats created by diverse molecular simulation packages and supports various force field parameters. In addition to the MM/PB(GB)SA toolkits listed above, several Web servers based on MM/PB(GB)SA have been developed and are open to all users. ACFIS, a Web server for fragment-based drug discovery, was developed in order to improve the effectiveness of drug discovery.238 CAND_GEN, one of the three computational modules in ACFIS, is a tool to generate hit candidates. Users can choose a binding free energy calculation method (MM/PBSA or MM/GBSA) to rescore the hit candidates. SAMPDI was designed to predict changes in protein−DNA binding free energies upon missense mutations using a modified MM/PBSA approach.239 More recently, we developed a Web server for fast AMBER rescoring for PPI inhibitors (farPPI) that offers a freely available service for rescoring the docking poses for PPI inhibitors using MM/ PB(GB)SA methods.240\nAlthough MM/GBSA is more computationally efficient than most end-point free-energy calculation methods, it still takes much more time than the scoring functions commonly used in protein−protein docking. Hence, some scoring functions based on energetic terms extracted from the MM/PB(GB)SA methods have been developed and applied for molecular docking.187 PBSA_E, a new free energy estimator based on the MM/PBSA descriptors, was developed by Zhang et al.241 Chowdhury et al. refined docking protocols using shape complementarity, electrostatics affinity functions, and knowl-\nedge-based interface propensity and utilized the GBSA solvation energy to rerank the structures.242 The time cost of MM/GBSA is mainly used to calculate the polar desolation energy term based on the GB model. In response to that point, our group developed HawkRank, a force-field-based scoring function with energy terms similar to those in MM/GBSA.243 Our results show that HawkRank yields better predictions than three other scoring functions, namely, ZRANK,244 FireDock,245 and dDFIRE,246 according to the total number of hits and modified success rate (MSR). Moreover, MM/GBSA rescoring is competent to distinguish correct protein−protein binding structures from decoys, and the use of HawkRank followed by MM/GBSA rescoring is an efficient protocol to improve the predictions of protein−protein docking."
    }, {
      "heading" : "7. APPLICATIONS IN SMALL-MOLECULE DRUG DESIGN",
      "text" : "With the advantage of requiring much lower computational cost while giving prediction accuracy comparable to that of the much more time-consuming pathway methods (i.e., FEP and TI), MM/PBSA and MM/GBSA have been widely used in the field of small-molecule drug design, such as in postprocessing of structure-based virtual screening. Moreover, they are also very useful tools for analyzing the binding details of drug− target interactions since they can be conveniently decomposed into different energy terms (eqs 5−8) to capture vital region/ residue receptor−ligand interactions, which are very important for rational drug design. In this section, we will review the associated progress of using MM/PB(GB)SA in smallmolecule drug design."
    }, {
      "heading" : "7.1. Applications in Virtual Screening",
      "text" : "In the early stages of structure-based virtual screening, large compound databases are usually screened using scoring functions from molecular docking to identify promising drug candidates. In molecular docking, with the conformation of a protein target determined from X-ray, NMR, or theoretical modeling, a ligand is brought close to the specific binding site of the target, and then the possible poses and conformations of the ligand are sampled. For the sake of fast computation, simple scoring functions are usually employed to estimate the binding affinity for a given docking pose. Some important energy terms, such as the solvation free energy, are simplified or totally ignored in most docking scoring functions. Therefore, a single docking scoring function may have difficulty in correctly predicting the binding poses and binding affinities in virtual screening.247 Hence, more advanced computational methods are needed for molecular docking in rational virtual screening.248−254 In many cases, the combination of molecular docking and MM/PB(GB)SA rescoring has proven to be a promising strategy in both the identification of the correct binding poses and the correct ranking of the binding affinities of a series of ligands.94,96,101,255−261 For example, Sgobba et al. assessed the “screening power” of the MM/PB(GB)SA approaches in rescoring the docking conformations of ligands targeting six drug targets,96 and they found that in most cases MM/GBSA can give a higher area under the curve (AUC) value and enrichment factor compared with the traditional docking approaches. A similar conclusion was derived by Zhang et al., who enlarged the assessment to 38 drug targets in the DUD database with up to ∼0.7 million actives and decoys.258 Besides assessing the screening power of the MM/PB(GB)SA rescoring, our group\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nM\nalso assessed the “docking power” of MM/PB(GB)SA to 98 targets, and we found that MM/GBSA rescoring can markedly improve the ratio of finding the correct binding poses of ligands in most cases (successful rate = 69.4%).101 The definition of each assessment based “power” in molecular docking is fully presented in Liu’s work.262\nIn the past decades, the use of MM/PB(GB)SA in virtual screening has been limited to as many as a few hundred of the top docking hits.95 However, with the dramatic increase ing computer power in recent years, MM/PBSA and MM/GBSA have been applied for rescoring of thousands of compounds prescreened by molecular docking.94,258,259 The potential power of the MM/PB(GB)SA approaches in discriminating true binders from a much larger number of decoys (the socalled screening power) has been demonstrated in highthroughput virtual screening studies.96,263−268 For instance, using the MM/GBSA approach, Amato et al. identified a set of chemical fragments targeting PHD zinc fingers (a target once considered with low ligand ability), and they also successfully crystallized the first complex with a chemical fragment binding in the anchoring pocket of the histone binding site of PHD zinc fingers.265 Moreover, Li’s group carried out docking-based virtual screening with MM/GBSA rescoring for human dihydroorotate dehydrogenase (hDHODH).264 They successfully identified a series of hDHODH inhibitors, and the best inhibitor from their initial virtual screening has an IC50 of 110 nM. A similar example was also reported by Ferreira de Freitas et al., who used MM/GBSA rescoring for the initial virtual screening and found a series of low-micromolar inhibitors targeting the HDAC6 zinc-finger ubiquitin binding domain.266 Besides, our group employed MM/GBSA to identify actives targeting different drug targets, such as macrophage migration inhibitory factor (MIF)269 and anaplastic lymphoma kinase (ALK).270 All of the studies found nanomole-level actives, implying that the use of end-point methods such as MM/ GBSA is indeed a very promising approach in virtual screening. Besides the applications in virtual screening, the end-point approaches have been also used in the lead optimization stage of drug design campaigns for fast and accurate prediction of the binding affinities of the newly modified compounds.68,73,271−274 Recently the capability of MM/PB(GB)SA rescoring in lead optimization has been investigated, and more and more advanced molecular simulations and free energy calculations with MM/PB(GB)SA have been successfully applied to the optimization of lead compounds.73,275−277 For instance, by employing molecular docking and MM/GBSA rescoring, Xu et al. successfully found and optimized several novel-scaffold selective inhibitors targeting PfDHODH,268 where the best optimized inhibitor has an IC50 of 6 nM with 40% oral bioavailability and >14000-fold species selectivity over hDHODH. Taddei et al. also used MM/GBSA to design and optimize a series of inhibitors with the 1,4,5-trisubstituted 1,2,3-triazole scaffold targeting Hsp90,277 in which one compound, SST0287CL1, was shown to have in vitro and in vivo activities comparable to those of the clinically tested Hsp90 inhibitor NVP-AUY922. Moreover, our group also employed MM/GBSA to analyze, design, and optimize antiresistant ALK inhibitors, and in that work we found what is to our knowledge the best antiresistant inhibitor (IC50 = 0.27 nM) with very high binding selectivity in 35 kinases.270\nThe above discussions have shown numerous successful cases of using the end-point methods for rational drug design or lead optimization. However, as a theoretical method whose\nparameters come largely from finite experimental sources, these methods may also be biased to some well-tested systems and fail to correctly identify the true binders from the decoys in many cases. To alleviate this problem, our group proposed an energy-decomposition-based virtual screening method named MIEC-SVM,277,278 which combines molecular interaction energetic components (MIECs) derived from the MM/ GBSA decomposition and machine learning methods (support vector machine, SVM) to construct personalized prediction models to distinguish actives from decoys. This method has been successfully used in many cases such as designing novel inhibitors for ALK279 and distinguishing binders from nonbinders for luciferase,280 HIV-1 protease,278,281,282 etc. In the case of ALK, we successfully identified seven strong novel inhibitors (<10 μM), four of which show nanomole-level activities.279 All of the cases shown above imply that the endpoint methods are indeed very promising tools for rational drug design. Although MM/PBSA and MM/GBSA have been successfully applied in virtual screening, optimization of lead compounds, and detailed binding analyses, the prediction results are sensitive to many calculation conditions, such as the atomic charges, interior dielectric constants, MD simulation length, entropy calculations, etc.88,97,99 Different settings may result in very different binding affinities even for the same system in study. Thus, one should keep in mind that system dependence always exists and that the selection of appropriate computational techniques depends on the characteristics of the studied system and the information available. Currently there is no universally accurate and reliable solution within reach, and innovative approaches are definitely needed, e.g., to tackle the problems arising from target flexibility and solvent molecules residing inside or around the binding pocket."
    }, {
      "heading" : "7.2. Analysis of Critical Interactions for Rational Drug Design",
      "text" : "As mentioned above, MM/PBSA and MM/GBSA are powerful tools in optimizing lead compounds because they can quantitatively characterize the binding details (such as analyzing critical interactions) of ligand−receptor systems.270,283−288 In drug−target interactions, it has been suggested that the electrostatic interaction dominates the non-covalent binding in molecular recognition.289 However, this is not generally true, as it is well-known that shape complementarity is also very important.290 Molecular recognition can therefore be attributed to contributions from both electrostatic and van der Waals interactions, solvation/ desolvation and entropy effects. With a computing framework in hand, numerous studies have employed the MM/PB(GB)SA approaches to analyze the critical interactions in ligand− receptor pairs.277,283−285,291 For example, by using MD simulations and MM/GBSA free energy decomposition, Jiang et al. analyzed the binding mechanism of known inhibitors targeting Keap1285 and then designed a series of high-bindingaffinity inhibitors to disrupt the protein−protein interaction between Keap1 and Nrf2 (a target that modulates many kinds of cancers and other chronic diseases292,293). In the designed inhibitors, one compound (compound 2) for the first time reached single-digit-nanomolar activity (Kd = 3.59 nM) and showed better pharmacological properties as well. Barril et al. used molecular docking, MD simulations, and MM/PBSA calculations to investigate the binding modes for agonists targeting REV-ERBα/NCoR,294 and among the four tested\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nN\ncompounds, three were validated with activities in their experiments. Moreover, in Kocakaya’s work, MD simulations were performed for PTP1B to reveal possible mechanisms of ligand recognition and inhibition,295 and MM/GBSA free energy decomposition was performed to give the detailed binding mechanism. The energy decomposition analysis suggested that potent and selective PTP1B inhibitors could possibly be designed by targeting the surface residues. The results were extremely consistent with the experimental work,296 in which residues such as Arg47, Asp48, Val49, Lys120, Ala217, Ile219, Gly220, Met258, and Thr263 had been confirmed to play an important role in modulating the activities. Besides, Mena-Ulecia et al. performed a comprehensive analysis of the binding specificity of 177 thrombin inhibitors using a three-dimensional quantitative structure− activity relationship (3D-QSAR) and end-point free energy calculations.297 Through these analyses, they inferred the effects of van der Waals contacts, electrostatic interactions, and solvation on the effectiveness of thrombin inhibitors. In addition, our group elucidated the binding mechanisms of type-I1/2 ALK inhibitors using umbrella sampling (US) simulations and MM/GBSA binding free energy decomposition analysis.298 We found that several residues in the hinge region (Leu1122, Leu1198, Gly1202, and Glu1210) and the allosteric pocket (Glu1197, Ile1171, Phe1174, Ile1179, His1247, Ile1268, Asp1270, and Phe1271) of ALK play vital roles in determining the relative binding strength of the studied inhibitors. The above examples suggest that the MM/ PB(GB)SA methods are powerful tools in analyzing the vital regions/residues for drug−target interactions, which have been proven to provide important information for rational drug design. Moreover, with the capability of fast characterization of the vital protein−ligand interactions, another highly useful application of MM/PB(GB)SA is to analyze the drug resistance mechanism, as they can provide more details on the energetic difference between the wild-type and mutated systems.288,291,299−305 By virtual mutagenesis technology, one can explain how a specific mutation influences the binding of a drug to its target since the drug-resistant mutants can usually reduce the binding affinity of a drug to its target and/or change the pocket conformation of the target.301,304,306−314 For instance, numerous drug-resistant mutations have been detected in ALK tyrosine kinase for nearly all of the launched drugs.315−320 Using the MM/GBSA approach, a recent study revealed that the L1198F mutation of ALK results in a conformational change of the binding pocket and alters the binding affinity of ALK to the launched drugs crizotinib and lorlatinib,321 where the critical amino acids identified by MM/ GBSA free energy decomposition are in agreement with the experimental results.319,322,323 Besides, Zhang’s group investigated the resistance mechanisms of ALK mutations (I1171N, V1180L, and L1198F) to alectinib by means of MD simulations and end-point binding free energy calculations.324\nThey presented a “key and lock” mechanism between the ethyl group at position 9 of alectinib and a recognition cavity in the hinge region of ALK to illustrate the major molecular origin of drug resistance. Our group has also done several works to analyze the crizotinib resistance mechanisms for ALK using the end-point methods, including the effects of the C1156Y, G1202R, R1152L, and S1206Y mutations, and the simulation results show that both the entropy effect and long-range\nindirect interactions can attenuate the binding of crizotinib.307,325\nThanks to the theoretical analysis tools, many pioneering works have successfully designed a number of antiresistant inhibitors to overcome drug-resistant mutations, such as L1196M, G1202R, C1156Y, etc. in ALK270,326−328 and A421V, A156T, R155K, etc. in HCV,287,329 which is encouraging for researches who want to use the end-point binding free energy calculation approaches for rational antiresistant drug design."
    }, {
      "heading" : "8. APPLICATIONS IN MACROMOLECULAR INTERACTIONS",
      "text" : "As powerful end-point binding free energy calculation tools, MM/PBSA and MM/GBSA have also been widely used in many other fields besides small-molecule drug design. For example, a very useful application of MM/PB(GB)SA is to predict the interactions between macromolecules, such as p ro t e i n−p ro t e i n , 9 3 , 2 0 9 , 2 4 3 , 3 3 0− 3 3 5 p ro t e i n−pep - tide,278,283,336−341 and protein−nucleic acid interactions.100,239,342−352 At present, calculations of the absolute binding free energies for these problems remain very challenging for alchemical methods."
    }, {
      "heading" : "8.1. Applications in Protein−Protein Interactions",
      "text" : "PPIs play crucial roles in most biological processes in living cells,353−355 and numerous PPIs have been considered as potential drug targets.356−358 The 3D structure of a protein− protein complex can provide a global scope of how and where one protein interacts with another. Nowadays, a variety of experimental techniques have been developed to explore whether there are interactions between two proteins.359 However, it is hard to determine how two proteins interact through most of the biophysical and/or biochemical techniques without detailed structural information.360−362 Although there are limitations, X-ray crystallography, cryogenic electron microscopy (cryo-EM), and NMR techniques are able to determine the native structure of a protein monomer or a protein−protein complex at the atomic level,363 but solving the high-resolution structures for all of the PPIs is a considerably more difficult or even impossible task.364,365 Therefore, computational methods have become alternatively popular to explore the interactions between two proteins in a complex.366,367\nProtein−protein docking, which can predict the binding affinities and binding modes between individual protein structures, is a powerful approach to predict PPIs.368 In principle, the stable conformation of a protein−protein complex can be computationally determined to be the structure with the minimum free energy on the potential energy surface.359 To date, many efforts have been made to develop protein−protein docking methods to determine and analyze PPIs, though using just molecular docking techniques to determine the energy minima from the huge conformational space is arduous.359 In practice, two phases are included in most protein−protein docking approaches: the docking phase and the ranking phase. In the first phase, extensive conformations are generated by molecular docking, and potential binding poses (also called decoys) are sampled from them. In the ranking stage, the decoys sampled during the first stage are scored and ranked using diverse scoring functions.368 To allow fast screening of large molecular databases, a hierarchical scoring scheme is usually applied by\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nO\nusing a coarse scoring function as a rapid filter of the entire database in the initial docking phase and then using a more rigorous but time-consuming scoring function to rescore the top hits to produce the final ranked queries.257\nFor rescoring of macromolecule interactions, the MM/ PB(GB)SA methods are thought to be greatly effective technologies since they often achieve a good balance between computational speed and accuracy compared with the alchemical methods (low in speed) and traditional molecular docking scoring functions (low in accuracy).93,243,331 For instance, Maffucci and Contini determined the relative binding free energies for a data set of 20 protein−protein pairs using a modified MM/PBSA approach (called Nwat-MM/PBSA)331 that explicitly incorporates the effects of water on the binding of the protein−protein pairs, and significant improvement was shown for the correlation between the predicted results and the experimental data (r2 = 0.77, compared with 0.45 for the traditional method). We also assessed the ability of MM/PBSA and MM/GBSA to predict the binding affinities for 46 protein−protein complexes.93 Our results show that MM/ GBSA rescoring is better than ZDOCK scoring for differentiating the correct binding structures from the decoys. Therefore, considering the low computational cost and relatively high prediction accuracy, MM/GBSA is potentially an alternatively powerful tool to predict binding affinities and identify correct binding structures for protein−protein systems. Moreover, to understand the details of protein−protein interactions, one can utilize sequence, structure, and energybased features to reveal the binding mechanisms, such as vital residues, mutation effects, and hot spots.207,369,370 Petukh et al. proposed a new method called SAAMBE that combines structure minimization and a modified MM/PBSA approach to estimate the effects of single and multiple mutations on protein−protein binding and suggested a crucial role of the water model and polar solvation energy in predicting the binding affinity.371 The core of this modified MM/PBSA method is to use a residue-specific dielectric constant protocol to characterize the mutation effects, and it achieves a good correlation (rP = 0.75) between the predictions and the experimental data for 1300 mutations in 43 proteins. Besides, alanine scanning, proposed by Massova and Kollman in 1999,372 is another useful technology to analyze hot spots for PPIs. Combined with the MM/PB(GB)SA methods, this technology has proven to be a very useful approach for revealing specific features of protein−protein interactions, and it has been successfully applied to insulin dimer,373 IGF-II/ IGF2R,374 Ras−Raf and Ras−RalGDS,72 etc. For example, the hot spots in the IGF-II/IGF2R complex identified by MM/ PB(GB)SA-based alanine scanning374 are consistent with the reported experimental mutagenesis data.375−378\nBesides their applications in PPI predictions, the MM/ PB(GB)SA methods are usually used in studies of protein− peptide interactions (PpIs), which is also a very important field for molecular design since PpIs can mimic the interaction patterns of protein−protein systems to regulate biological processes.278,283,336−340 For example, using MD simulations and MM/GBSA free energy analyses, Xu et al. studied the binding pattern of an eight-residue peptide targeting TNKS and subsequently designed several constrained peptide inhibitors (called macrocyclized extended peptides) that can effectively inhibit the biological activity of the target and overcome the off-target phenomenon.283 Moreover, the abovementioned MIEC-SVM method proposed by our group has\nbeen successfully used in many protein−peptide systems, such as chromodomain-methyllysine-binding peptides,339 ABL1SH3-binding peptides,278,340,341 PKA-RIIα-binding peptides,338 etc., where many predicted tight-binding peptides have been validated by experimental assays.339−341"
    }, {
      "heading" : "8.2. Applications in Protein−Nucleic Acid Interactions",
      "text" : "Besides protein−protein/peptide interactions, protein−nucleic acid (RNA/DNA) interactions also play crucial roles in many biological processes, such as regulation of gene expression, RNA splicing, protein synthesis, etc. Most RNAs function only when in complex with specific proteins. Therefore, revealing the specific protein−RNA recognitions and binding patterns is crucial for both understanding the important processes of life and designing new drugs.379 Partly because the existing scoring functions for protein−RNA interactions (PRIs) are unreliable, accurately predicting the 3D structures and binding affinities for PRIs is still quite difficult. To solve this problem, the MM/ PB(GB)SA approaches have also been employed in studying the PRIs.347,348,352 For instance, Orr et al. presented a computational tool to accurately characterize the interactions between proteins and RNA with post-transcriptional modifications,348 in which they used MM/GBSA to predict whether an RNA modification is favorable for binding with the target protein, and the predictions showed a very high correlation with the experimental data (r2 > 0.9). Moreover, we systemically investigated the performance of MM/PBSA and MM/GBSA to predict the binding affinities and identify the near-native binding structures for 148 protein−RNA systems with different solvent models and solute dielectric constants.100 The results showed that MM/GBSA rescoring efficiently improves the prediction capability of the scoring functions for protein−RNA systems (rP = 0.58), especially for the binding poses generated from ZDOCK_M, a modified ZDOCK program.380\nWith regard to protein−DNA interactions (PDIs), several recent theoretical works involving mechanistic analyses350,351,381−383 and methodology development239,349 have been reported. For example, Peng et al. developed a modified MM/PBSA method to predict the binding free energy difference arising from missense mutations to protein−DNA complexes,239 and a high correlation coefficient (rP = 0.72) was reached for the test set containing 105 mutations covering 13 protein−DNA systems. Moreover, combining fast side-chain optimization algorithms and the MM/PBSA approach, Li’s group developed a new algorithm called PremPDI to predict the effects of missense mutations on the binding of protein− DNA complexes.349 In a data set of 49 protein−DNA complexes containing 219 mutations, they also achieved a high Pearson correlation coefficient between the predicted results and the experimental data (rP = 0.71). All of these examples imply that the use of end-point binding free energy calculation methods to predict macromolecule interactions is feasible. The ribosome is the place where protein synthesis occurs, and in bacteria it consists of small (30S) and large (50S) subunits with tens of proteins and a sequence of rRNAs.384,385 The synthesis of a protein starts with binding of an mRNA to the ribosomal 30S subunit, and then in the elongation phase the nascent peptide is extended with local folding from the peptidyl transferase center (PTC) through an internal tunnel into the large ribosomal 50S subunit.386,387 Finally, the nascent peptide escapes from the tunnel and folds into its native\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nP\nstructure with the help of other factors.388 This process involves multiple interactions, including the binding of peptide/antibiotics to rRNAs or proteins.389−392 The MM/ PBSA method was first used to investigate the binding of aminoglycoside derivatives to the A site of the ribosome, and the predicted binding free energies were found to be in good agreement with the experimental values.393 Moreover, MD simulations suggested that additional stability to the bases A1492 and A1493 in their extrahelical forms is provided by well-designed compounds. A conformational transition in the aminoacyl tRNA site of the bacterial ribosome both in the absence and presence of an aminoglycoside antibiotic was reported by Mobashery et al.394"
    }, {
      "heading" : "9. QM IN MM/PB(GB)SA CALCULATIONS",
      "text" : "Although the MM/PBSA and MM/GBSA methods have been successfully applied to many problems, particularly in estimating free energies for binding of small ligands (drug candidates) to proteins, it is well-known that the MM energy model has some limitations for accurate prediction of free energy. Although sufficient sampling is required for suitable convergence of free energy calculations, the results strongly depend on the quality of the MM potential. For some interesting systems, such as transition states and metal-binding sites, the standard MM potentials may perform poorly. Hence, it is desirable to utilize the more versatile QM approaches for these systems.395−398 However, it remains true that the highest levels of QM can be used only for reasonably modest system sizes (tens of atoms).399 A number of general strategies have been employed to further extend the size of systems to which QM calculations can be applied. One of the most popular approaches is to describe a subregion of interest via QM and couple it to its larger environment modeled at the MM level (so-called QM/MM simulation). The fragment molecular orbital (FMO)400−402 method and linear scaling strategies398,403 are usually used to increase the reach of QM methods. Another useful strategy is to use a truncated system for the QM calculation. It has been reported that the average truncation error of QM calculations does not reach 1 kJ/mol with the radius of the system truncated to 8.5 Å after the MD simulation of the full-length protein system.404 Recently, the adaptation of QM algorithms to utilization of GPU architectures has also been reported.405\nNowadays, QM has been widely applied in the prediction of protein−ligand docking,120,123,406−410 protein−ligand binding affinities (scoring),411−415 and changes in ligand internal energy upon binding (ligand strain).416−418 For example, Raha and Merz used semiempirical QM to design a scoring function (QMScore) and calculated the solvation free energies and electrostatic interactions for a diverse set of 165 protein− ligand complexes.411 They obtained encouraging results that the square of the correlation coefficient between the predicted and experimental values reached up to 0.55. Moreover, comparison of QMScore with 11 other scoring functions for a set of 56 protein−ligand complexes from Wang’s data set419 showed that QMScore gave the best performance. Wu et al. studied the binding mechanism of L86 and T76 to human αthrombin using the molecular fractionation with conjugate caps (MFCC) and MM/PBSA approaches, and the results showed that the L86/T76-thrombin binding interactions given by MFCC and MM/PBSA are consistent and in good agreement with the experimental data.396\nRyde et al. proposed an approach to predict free energies of reactions in proteins, called QM−MM/PBSA.395 In their approach, the internal energy of the reactive site is calculated via QM, while the internal interactions with the surrounding protein are computed at the MM level. They found that QM− MM/PBSA reproduced the results of a strict QM/MM FEP method with a MAD of 8−10 kJ/mol if multiple frames extracted from the MD trajectories were employed and 4−14 kJ/mol if a single QM/MM structure was employed. Sippl et al. applied QM−MM/PBSA rescoring to search for novel Myt1 kinase inhibitors.410 The QM−MM/GBSA scoring performed better than docking scoring functions or MM/ PB(GB)SA in discriminating active from inactive compounds and could be used on a data set with diverse scaffolds. More recently, Mishra and Koca assessed the performance of the MM/PBSA, MM/GBSA, and QM−MM/GBSA approaches on protein−carbohydrate complexes.107 On the basis of the GBHCT model and the PM6 or DFTB method, QM−MM/ GBSA resulted in a marginally improved agreement (r2 = 0.96) with the experimental binding energies compared with MM/ PBSA with the mbondi radii set, indicating that the QM Hamiltonian may have a notable impact on the QM−MM/ GBSA predictions. They suggested that PM6 may be more suitable for virtual screening involving thousands of compounds because the DFTB/SCC-DFTB calculations are computationally much more demanding. In another work based on 6 ns MD simulation trajectories together with GBGBn2, PM3, and the mbondi2 radii set, QM−MM/GBSA generated the best correlation with the experimental results (r2 = 0.88).87 However, inclusion of QM methods does not always improve the prediction results of binding affinities and sometimes can even lead to much worse predictions than MM methods.188,415,420 Ryde et al. used this approach to estimate the binding affinities of ligands to cathepsin B, and the results indicated that the QM−MM/PBSA predictions (r2 = 0.59) were much worse than the predictions based only on gasphase QM energies (r2 = 0.80),421 whereas accurate QM− MM/PBSA predictions were obtained for cytochrome P450,422 highlighting the system dependence of QM−MM/ PB(GB)SA. Many more details are provided in the outstanding review of the use of QM in the prediction of ligand binding affinities.423"
    }, {
      "heading" : "10. COMPARISON WITH OTHER PREDICTIVE METHODS",
      "text" : "The LIE method, another popular end-point approach, has usually been used to compare with MM/PB(GB)SA in binding free energy predictions,51,54,68,181,197 but it is difficult to determine which one is more accurate. However, it seems that the LIE approach is highly system-dependent.197 For example, the standard LIE method yields no correlation for the CB8 systems but an excellent correlation for the α-CD systems. Ryde et al. compared the computational efficiencies and accuracies of LIE and MM/PBSA and found that LIE is 2−7 times more efficient than MM/PBSA in computational cost.68\nThe much more rigorous alchemical methods (such as FEP and TI) have been compared with MM/PB(GB)SA. because of the inherent limitations of the MM/PB(GB)SA approaches, they are less accurate than the alchemical methods78,271,273,424,425 in many cases. However, in some cases, the MM/PB(GB)SA methods give comparable182,426 or even better427 predictions than the alchemical methods.\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nQ\nScoring functions are more computationally efficient and are widely used in the early stage of virtual screening and estimation of binding free energies of protein−ligand interactions. Generally, however, the classical scoring functions are inherently inaccurate. For example, we evaluated the performance of MM/PB(GB)SA to predict the binding free energies and identify the correct binding conformations for 98 protein−ligand complexes, and the results showed that MM/ GBSA performed better than almost all of the scoring functions in molecular docking to identify the correct binding structures and rank the binding affinities for the tested protein−ligand systems.101 Another comparative evaluation study reported by Obiol-Pardo and Rubio-Martinez428 suggested that compared with XScore,429 MM/PBSA performed better in identifying small differences upon ligand binding for seven XIAP−peptide complexes. In recent years, machine-learning scoring functions for molecular docking have rapidly developed,430−434 but reviewing the advances of machine learning in drug design and PPIs is beyond the scope of this review."
    }, {
      "heading" : "11. CONCLUDING REMARKS",
      "text" : "Free energy calculations offer an estimation of the energy differences between thermodynamic processes given a series of specific parameters and physical hypotheses. A good free energy estimation approach aims to achieve convergence to a unique value solely determined by the free energy model (such as MM/PBSA or MM/GBSA) itself. This unique value is called the “correct” free energy of a given molecular system for the model. A free energy model can be improved by adjusting the employed parameters to reproduce the experimental data. It is critical to apply the “correct” free energies in the fitting procedure, and care must be taken to avoid overfitting. MM/PB(GB)SA calculations are popular because they provide a good balance between computational speed and accuracy. The performance of the predictions depends on both the sampling accuracy of the entire conformation space and the quality of the free energy model. To obtain the “correct” free energy for a molecular system with MM/PB(GB)SA calculations, many independent simulations for sampling may be necessary to achieve reasonable convergence. In practice, however, the MM/PB(GB)SA free energies may deviate away from the “correct” values because of inadequate conformational sampling, leading to a poor MAD even though the relative free energies measured by r2 are still satisfactory. An MM/PB(GB)SA model is a combination of functional forms for different energy terms and the associated parameters, such as the force fields for molecular mechanics energies and the solute dielectric constants and atomic radii for solvation free energies calculated with the PB/GB theories. These parameters fundamentally affect the predictive accuracy of various energy terms. The solvation free energy is a pivotal term since the solvent effect plays a key role in protein−protein/ligand binding, protein tertiary structure formation, and execution of protein functions. Thus, an accurate treatment of the solvation term is fundamental to compute binding free energies. The polar contribution of the solvation free energy is predicted by solving the PBE. Unfortunately, PBE solvers do not converge with respect to the numerical grid used, except for MIBPB. Theoretically, the PB method for solving the PBE is more accurate than GB. However, the GB model has gained popularity because of its favorable computational speed and\ncomparable or even better accuracy compared with the PB method. The dielectric constant strongly impacts the prediction of the polar solvation free energy, and the variable dielectric model illustrates potential power. The nonpolar contribution of solvation free energy is represented by a linear relation to the SASA. To our knowledge, in recent years nonpolar solvation energy predictions have become less attractive, and we hope that many efforts will be made in the future. It is noted that the MM/PB(GB)SA free energy model may be unable to perform well when a binding site involves a highly charged environment, for which an accurate treatment of electrostatic interactions is crucial for binding free energy calculations. The calculation uncertainty increases with the polarity of the studied compounds, especially when polar compounds bind to a binding pocket formed by highly charged residues located in the interior of a biomacromolecule. Furthermore, the contribution of structural water molecules residing inside or around the binding pocket cannot be taken into account well in binding free energy calculations with implicit solvation models. Explicit consideration of such water molecules in free energy calculations may significantly improve the accuracy of an MM/PB(GB)SA model. Another main source of error for MM/PB(GB)SA free energy models is the conformational entropies, which are typically estimated by performing NMA. As the anharmonic contribution is neglected in NMA, the conformational entropies obtained using NMA may have systematic errors for some molecular systems. A universally accurate and reliable solution is currently out of reach, and innovative methods are much needed. Using the PB method to calculate the electrostatics of large systems in high-throughput virtual screening requires large computational resources, including computing time and memory. Therefore, it is necessary to speed up PB calculations via parallelization on multiple CPUs or GPU acceleration. Nevertheless, MM/PBSA and MM/GBSA perform better in determining relative free energies and can be used for postprocessing of docked structures or to rationalize observed differences. However, they cannot serve as a basis for developing more accurate methods and predict true drug candidates in drug design without experimental verification because of their relatively limited accuracy (compared with FEP and TI). Despite this, the end-point free energy techniques are expected to play a more and more important role in detailed energetic investigations of complex formation as the MM/PB(GB)SA free energy models are continually improved in the future. Lastly, it is worth mentioning that machine learning and mathematical methods, especially the former, have gained much popularity recently. However, it is beyond the scope of the current review to discuss these methods here. Critical Analysis and Remaining Challenges: With the well-defined algorithms and good balance between computational efficiency and prediction accuracy, MM/PBSA and MM/GBSA have been regarded as competitive methods in the field of binding free energy calculations, and they have been successfully applied in many aspects of drug design, including structure-based virtual screening, lead optimization, and molecular recognition. However, their computational efficiency is achieved by introducing controversial approximations to both the sampling and energy calculation phases, such as using a uniform dielectric constant for the whole solute surrounded by a complicated local microenvironment, ignoring or\nDOI: 10.1021/acs.chemrev.9b00055 Chem. Rev. XXXX, XXX, XXX−XXX\nR\nimproperly treating ions and critical water molecules in the binding site, ignoring or applying oversimplified methods to estimate conformational and solvation entropies, etc. Fortunately, the performance of MM/PBSA and MM/GBSA can be further improved by taking some remedial measures and introducing new techniques to them. First, MM/GBSA based on a variable dielectric model, in which variable dielectric constants are assigned to different residues in a protein− protein/ligand complex, could be a good idea. As a matter of fact, we believe that the variable dielectric model is one of the most promising ways to make a breakthrough in the two endpoint free energy methods. Second, the implementation of MM/PB(GB)SA on GPUs will greatly accelerate the sampling and energy calculations. Moreover, artificial intelligence, from artificial neural networks to deep learning, may find great applications in MM/PB(GB)SA-based binding free energy calculation and structure prediction in the coming years, especially when big data of high-quality experimental structures and binding data become available.\nAUTHOR INFORMATION Corresponding Authors\n*E-mail: tingjunhou@zju.edu.cn (T.H.). *E-mail: john.zhang@nyu.edu (J.Z.H.Z.). ORCID\nHuiyong Sun: 0000-0002-7107-7481 Junmei Wang: 0000-0002-9607-8229 Hui Liu: 0000-0002-1267-2475 John Z. H. Zhang: 0000-0003-4612-1863 Tingjun Hou: 0000-0001-7227-2580 Author Contributions ∇E.W. and H.S. contributed equally. Notes\nThe authors declare no competing financial interest.\nBiographies\nErcheng Wang received his Ph.D. in physics from Huazhong University of Science and Technology (HUST), working on theoretical studies of the cotranslational protein folding mechanism. He is currently a postdoctoral fellow in the College of Pharmaceutical Sciences at Zhejiang University, where his research focuses on computational studies of protein−protein/ligand interactions and method development for binding free energy calculations.\nHuiyong Sun received his Ph.D. from the Institute of Functional Nano & Soft Materials (FUNSOM) at Soochow University. Currently he is an associate professor in the School of Pharmacy at China Pharmaceutical University. His research interest is in computer-aided drug design. To date he has coauthored more than 50 publications in peer-reviewed journals.\nJunmei Wang received his Ph.D. from Peking University and then studied as a postdoctoral associate with Dr. Peter Kollman at the University of California San Francisco. Currently he is an associate professor of computational chemistry and biophysics and a member of the Computational Chemical Genomics Screening Center in the School of Pharmacy at the University of Pittsburgh. He and his collaborators developed a set of popular AMBER force fields (FFs), such as FF99, GAFF, and polarizable FFs based on atomic dipole interactions, as well as the Antechamber module implemented in AMBER. He has published ∼100 papers in peer-reviewed journals with an h-index of 36.\nZhe Wang received his B.S. from Wenzhou Medical University. He is currently a Ph.D. candidate in the College of Pharmaceutical Sciences at Zhejiang University. His research focuses on the development, evaluation, and optimization of combined strategies for structurebased virtual screening.\nHui Liu obtained his B.S. in pharmacology in 2005 and his Ph.D. in biology in 2010 from Wuhan University. Then he undertook postdoctoral research in the laboratory of Tingjun Hou at Zhejiang University, and he is currently an associate professor at Huazhong Agricultural University. His research focuses on molecular simulations and computer-aided drug design.\nJohn Z. H. Zhang received his Ph.D. in chemical physics in 1987. His current research focuses on computational studies of biomolecular systems, including protein−ligand binding, protein−protein interaction, protein design, etc. He is currently the director of the NYU− ECNU Center for Computational Chemistry at NYU Shanghai and a professor of chemistry at NYU Shanghai and ECNU. He has won many awards and fellowships, including the Camille and Henry Dreyfus New Faculty Award (1990), the National Science Foundation Presidential Faculty Fellowship (1994), the Alfred P. Sloan Foundation Research Fellowship (1995), and the Camille Dreyfus Teacher-Scholar Award (1995). He has over 350 publications in peerreviewed journals with an h-index of 55.\nTingjun Hou received his Ph.D. in computational chemistry from Peking University in 2002. His research focuses on molecular modeling and computer-aided drug design, including the development of structure-based virtual screening methodologies, theoretical predictions of ADMET and drug-likeness, discovery of small-molecule inhibitors toward important drug targets, and multiscale simulations of target−ligand recognition. Currently, he is a full professor in the College of Pharmaceutical Sciences at Zhejiang University and the director of the Drug Informatics and Computational Biology Center in the Hangzhou Institute of Innovative Medicine at Zhejiang University. He has coauthored more than 320 publications in peerreviewed journals with an h-index of 49."
    }, {
      "heading" : "ACKNOWLEDGMENTS",
      "text" : "This work was financially supported by the National Key R&D Program of China (2016YFA0501700 and 2016YFB0201700), the National Natural Science Foundation of China (21575128, 81773632, 21433004, and 91753103), the Innovation Program of Shangha i Munic ipa l Educa t ion Commis s ion (201701070005E00020), and the National Institutes of Health (R01-GM079383 and R21-GM097617)."
    } ],
    "references" : [ {
      "title" : "Basic Ingredients of Free Energy Calculations: A Review",
      "author" : [ "C.D. Christ", "A.E. Mark", "W.F. van Gunsteren" ],
      "venue" : "J. Comput. Chem",
      "citeRegEx" : "Christ et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Christ et al\\.",
      "year" : 2009
    }, {
      "title" : "Atomic-Level Characterization of the Structural Dynamics of Proteins",
      "author" : [ "R. O", "M.P. Eastwood", "J.A. Bank", "J.M. Jumper", "J. K Salmon" ],
      "venue" : "Science",
      "citeRegEx" : "O. et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "O. et al\\.",
      "year" : 2010
    }, {
      "title" : "The Many Roles of Computation in Drug Discovery",
      "author" : [ "W.L. Jorgensen" ],
      "venue" : "Science",
      "citeRegEx" : "Jorgensen,? \\Q2004\\E",
      "shortCiteRegEx" : "Jorgensen",
      "year" : 2004
    }, {
      "title" : "Best Practices in Free Energy Calculations for Drug Design",
      "author" : [ "M.R. Shirts" ],
      "venue" : "Methods Mol. Biol",
      "citeRegEx" : "Shirts,? \\Q2012\\E",
      "shortCiteRegEx" : "Shirts",
      "year" : 2012
    }, {
      "title" : "Perturbation” in Medicinal Chemistry",
      "author" : [ "S.Y. Noskov", "C. Lim" ],
      "venue" : "J. Med. Chem",
      "citeRegEx" : "Noskov and Lim,? \\Q2018\\E",
      "shortCiteRegEx" : "Noskov and Lim",
      "year" : 2018
    }, {
      "title" : "Free Energy Calculations and Ligand Binding",
      "author" : [ "V.B. Luzhkov", "J. Aqvist" ],
      "venue" : "Adv. Protein Chem",
      "citeRegEx" : "Luzhkov and Aqvist,? \\Q2003\\E",
      "shortCiteRegEx" : "Luzhkov and Aqvist",
      "year" : 2003
    }, {
      "title" : "Improvements, Trends, and New Ideas in Molecular Docking: 2012−2013 in Review",
      "author" : [ "E. Yuriev", "J. Holien", "P.A. Ramsland" ],
      "venue" : "J. Mol. Recognit. 2015,",
      "citeRegEx" : "Yuriev et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yuriev et al\\.",
      "year" : 2015
    }, {
      "title" : "Guide to Protein-Drug Binding Free Energy Calculations Using Distributed Computing",
      "author" : [ "C. X", "Y.Y. Shi", "F. Zhou", "L. Wang" ],
      "venue" : "Methods Mol. Biol",
      "citeRegEx" : "X. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "X. et al\\.",
      "year" : 2012
    }, {
      "title" : "Mutation in Subtilisin Bpn",
      "author" : [ "Y. Wu", "Y. Deng", "B. Kim", "L. Pierce", "G. Krilov" ],
      "venue" : "Proteins: Struct., Funct., Genet",
      "citeRegEx" : "L. et al\\.,? \\Q1993\\E",
      "shortCiteRegEx" : "L. et al\\.",
      "year" : 1993
    }, {
      "title" : "Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field",
      "author" : [ "T. S", "Y. Hu", "B. Sherborne", "Z. Guo", "D.M. York" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "S. et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "S. et al\\.",
      "year" : 2015
    }, {
      "title" : "Comparison of End-Point ContinuumSolvation Methods for the Calculation of Protein−Ligand Binding Free Energies",
      "author" : [ "S. Genheden", "U. Ryde" ],
      "venue" : "Proteins: Struct., Funct., Genet",
      "citeRegEx" : "Genheden and Ryde,? \\Q2012\\E",
      "shortCiteRegEx" : "Genheden and Ryde",
      "year" : 2012
    }, {
      "title" : "Predicting Binding Affinity in Computer-Aided Drug Design",
      "author" : [ "O.A. Adekoya", "N.P. Willassen", "I. Sylte" ],
      "venue" : "Protein Eng., Des. Sel. 1994,",
      "citeRegEx" : "Adekoya et al\\.,? \\Q1994\\E",
      "shortCiteRegEx" : "Adekoya et al\\.",
      "year" : 1994
    }, {
      "title" : "Prediction by Linear Interaction Energy Methods",
      "author" : [ "J. Miller", "P.A. Kollman", "D.A. Case" ],
      "venue" : "J. Comput.-Aided Mol. Des",
      "citeRegEx" : "J. et al\\.,? \\Q1998\\E",
      "shortCiteRegEx" : "J. et al\\.",
      "year" : 1998
    }, {
      "title" : "Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices",
      "author" : [ "D.A. Case" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Case,? \\Q1998\\E",
      "shortCiteRegEx" : "Case",
      "year" : 1998
    }, {
      "title" : "Macromolecular Solvation Effects",
      "author" : [ "A. Onufriev", "D. Bashford", "D.A. Case" ],
      "venue" : "Annu. Rev. Phys. Chem",
      "citeRegEx" : "Onufriev et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Onufriev et al\\.",
      "year" : 2000
    }, {
      "title" : "Converging Free Energy Estimates: MM-PB(GB)SA Studies on the Protein−Protein Complex Ras−Raf",
      "author" : [ "H. Gohlke", "D.A. Case" ],
      "venue" : "J. Comput. Chem",
      "citeRegEx" : "Gohlke and Case,? \\Q2004\\E",
      "shortCiteRegEx" : "Gohlke and Case",
      "year" : 2004
    }, {
      "title" : "Application to the TCR-P-MHC Complex. Proteins: Struct",
      "author" : [ "H. Gohlke", "C. Kiel", "D.A. Case" ],
      "venue" : "Funct., Genet",
      "citeRegEx" : "Gohlke et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Gohlke et al\\.",
      "year" : 2007
    }, {
      "title" : "Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method",
      "author" : [ "N. Homeyer", "H. Gohlke" ],
      "venue" : "Mol. Inf. 2012,",
      "citeRegEx" : "Homeyer and Gohlke,? \\Q2012\\E",
      "shortCiteRegEx" : "Homeyer and Gohlke",
      "year" : 2012
    }, {
      "title" : "Long Timescale Simulations",
      "author" : [ "V. Daggett" ],
      "venue" : "Curr. Opin. Struct. Biol. 2000,",
      "citeRegEx" : "Daggett,? \\Q2000\\E",
      "shortCiteRegEx" : "Daggett",
      "year" : 2000
    }, {
      "title" : "How To Obtain Statistically Converged MM/GBSA Results",
      "author" : [ "S. Genheden", "U. Ryde" ],
      "venue" : "J. Comput. Chem. 2009,",
      "citeRegEx" : "Genheden and Ryde,? \\Q2009\\E",
      "shortCiteRegEx" : "Genheden and Ryde",
      "year" : 2009
    }, {
      "title" : "The Accuracy of Ranking Poses Generated from Docking",
      "author" : [ "Methods. II" ],
      "venue" : "J. Comput. Chem. 2011,",
      "citeRegEx" : "II.,? \\Q2011\\E",
      "shortCiteRegEx" : "II.",
      "year" : 2011
    }, {
      "title" : "Interaction Entropy: A New Paradigm for Highly Efficient and Reliable Computation of Protein− Ligand Binding Free Energy",
      "author" : [ "L. Duan", "X. Liu", "J.Z. Zhang" ],
      "venue" : "J. Am. Chem. Soc. 2016,",
      "citeRegEx" : "Duan et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Duan et al\\.",
      "year" : 2016
    }, {
      "title" : "High-Resolution Crystal Structure of the Human CB1 Cannabinoid Receptor",
      "author" : [ "J. Wang", "D.M. Rosenbaum" ],
      "venue" : "Nature 2016,",
      "citeRegEx" : "Wang and Rosenbaum,? \\Q2016\\E",
      "shortCiteRegEx" : "Wang and Rosenbaum",
      "year" : 2016
    }, {
      "title" : "Exploring the Parameter Space",
      "author" : [ "Affinities" ],
      "venue" : "J. Chem. Inf. Model. 2007,",
      "citeRegEx" : "1.,? \\Q2007\\E",
      "shortCiteRegEx" : "1.",
      "year" : 2007
    }, {
      "title" : "Electrostatics in Biomolecular Structure and Dynamics",
      "author" : [ "M.E. Davis", "J.A. Mccammon" ],
      "venue" : "Chem. Rev. 1990,",
      "citeRegEx" : "Davis and Mccammon,? \\Q1990\\E",
      "shortCiteRegEx" : "Davis and Mccammon",
      "year" : 1990
    }, {
      "title" : "Progress in Developing Poisson−Boltzmann Equation Solvers",
      "author" : [ "C. Li", "L. Li", "M. Petukh", "E. Alexov" ],
      "venue" : "Mol. Based Math. Biol",
      "citeRegEx" : "Li et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2013
    }, {
      "title" : "A Rapid Finite-Difference Algorithm, Utilizing Successive over-Relaxation to Solve the Poisson−Boltzmann Equation",
      "author" : [ "A. Nicholls", "B. Honig" ],
      "venue" : "J. Comput. Chem. 1991,",
      "citeRegEx" : "Nicholls and Honig,? \\Q1991\\E",
      "shortCiteRegEx" : "Nicholls and Honig",
      "year" : 1991
    }, {
      "title" : "Calculating Total Electrostatic Energies with the Nonlinear Poisson−Boltzmann Equation",
      "author" : [ "K.A. Sharp", "B. Honig" ],
      "venue" : "J. Phys. Chem",
      "citeRegEx" : "Sharp and Honig,? \\Q1990\\E",
      "shortCiteRegEx" : "Sharp and Honig",
      "year" : 1990
    }, {
      "title" : "Poisson−Boltzmann Versus Size-Modified Poisson−Boltzmann Electrostatics Applied to Lipid Bilayers",
      "author" : [ "N. Wang", "S. Zhou", "P.M. Kekenes-Huskey", "B. Li", "J.A. McCammon" ],
      "venue" : "J. Phys. Chem. B",
      "citeRegEx" : "Wang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2014
    }, {
      "title" : "New Solution Decomposition and Minimization Schemes for Poisson−Boltzmann Equation in Calculation of Biomolecular Electrostatics",
      "author" : [ "D.X. Xie" ],
      "venue" : "J. Comput. Phys. 2014,",
      "citeRegEx" : "Xie,? \\Q2014\\E",
      "shortCiteRegEx" : "Xie",
      "year" : 2014
    }, {
      "title" : "A Nonlocal Modified Poisson−Boltzmann",
      "author" : [ "D.X. Xie", "Y. Jiang" ],
      "venue" : "Electrostatic Environments. J. Chem. Phys. 2016,",
      "citeRegEx" : "Xie and Jiang,? \\Q2016\\E",
      "shortCiteRegEx" : "Xie and Jiang",
      "year" : 2016
    }, {
      "title" : "Equation and Finite Element Solver for Computing Electrostatics of Biomolecules",
      "author" : [ "C. Tan", "Y.-H. Tan", "Q. Lu", "R. Luo" ],
      "venue" : "J. Comput. Phys",
      "citeRegEx" : "J. et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "J. et al\\.",
      "year" : 2016
    }, {
      "title" : "The Amber Biomolecular Simulation Programs",
      "author" : [ "R.J. Woods" ],
      "venue" : "J. Comput. Chem. 2005,",
      "citeRegEx" : "Woods,? \\Q2005\\E",
      "shortCiteRegEx" : "Woods",
      "year" : 2005
    }, {
      "title" : "Assessment of Linear Finite-Difference Poisson−Boltzmann Solvers",
      "author" : [ "J. Wang", "R. Luo" ],
      "venue" : "J. Comput. Chem. 2010,",
      "citeRegEx" : "Wang and Luo,? \\Q2010\\E",
      "shortCiteRegEx" : "Wang and Luo",
      "year" : 2010
    }, {
      "title" : "Performance of Nonlinear Finite-Difference Poisson−Boltzmann Solvers",
      "author" : [ "Q. Cai", "M.J. Hsieh", "J. Wang", "R. Luo" ],
      "venue" : "J. Chem. Theory Comput. 2010,",
      "citeRegEx" : "Cai et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Cai et al\\.",
      "year" : 2010
    }, {
      "title" : "Adaptive Multilevel Finite Element Solution of the Poisson−Boltzmann Equation I",
      "author" : [ "M. Holst", "N. Baker", "F. Wang" ],
      "venue" : "Algorithms and Examples. J. Comput. Chem. 2000,",
      "citeRegEx" : "Holst et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Holst et al\\.",
      "year" : 2000
    }, {
      "title" : "Improved Boundary Element Methods for Poisson−Boltzmann Electrostatic Potential and Force Calculations",
      "author" : [ "B.Z. Lu", "J.A. McCammon" ],
      "venue" : "J. Chem. Theory Comput",
      "citeRegEx" : "Lu and McCammon,? \\Q2007\\E",
      "shortCiteRegEx" : "Lu and McCammon",
      "year" : 2007
    }, {
      "title" : "Accurate, Robust, and Reliable Calculations of Poisson−Boltzmann Binding Energies",
      "author" : [ "D.D. Nguyen", "B. Wang", "G.W. Wei" ],
      "venue" : "J. Comput. Chem. 2017,",
      "citeRegEx" : "Nguyen et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Nguyen et al\\.",
      "year" : 2017
    }, {
      "title" : "GPU Linear and NonLinear Poisson−Boltzmann Solver Module for DelPhi",
      "author" : [ "J. Colmenares", "J. Ortiz", "W. Rocchia" ],
      "venue" : "Bioinformatics 2014,",
      "citeRegEx" : "Colmenares et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Colmenares et al\\.",
      "year" : 2014
    }, {
      "title" : "Acceleration of Linear Finite-Difference Poisson−Boltzmann",
      "author" : [ "R. Qi", "W.M. Botello-Smith", "R. Luo" ],
      "venue" : "Methods on Graphics Processing Units. J. Chem. Theory Comput. 2017,",
      "citeRegEx" : "Qi et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Qi et al\\.",
      "year" : 2017
    }, {
      "title" : "Method for Parallelization of Grid-Based Algorithms and Its Implementation in DelPhi",
      "author" : [ "L. David", "M.K. Gilson" ],
      "venue" : "J. Comput. Chem",
      "citeRegEx" : "R. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "R. et al\\.",
      "year" : 2012
    }, {
      "title" : "Carbonic Anhydrase as a Test Case: Strengths and Pitfalls of Each Approach",
      "author" : [ "C.R.W. Guimara ̃es", "A.M. Mathiowetz" ],
      "venue" : "J. Chem. Theory Comput. 2011,",
      "citeRegEx" : "̃es and Mathiowetz,? \\Q2011\\E",
      "shortCiteRegEx" : "̃es and Mathiowetz",
      "year" : 2011
    }, {
      "title" : "Virtual Screening Using Molecular Simulations",
      "author" : [ "K.N. Dalby", "P. Ren" ],
      "venue" : "Proteins: Struct., Funct., Genet",
      "citeRegEx" : "B. et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "B. et al\\.",
      "year" : 2011
    }, {
      "title" : "Surface Area-Based Model in Conformational Entropy Calculations",
      "author" : [ "S. Genheden" ],
      "venue" : "J. Chem. Inf. Model",
      "citeRegEx" : "Genheden,? \\Q2012\\E",
      "shortCiteRegEx" : "Genheden",
      "year" : 2012
    }, {
      "title" : "Calculation of Molecular Entropies Using Temperature Integration",
      "author" : [ "K. Sharp" ],
      "venue" : "J. Chem. Theory Comput. 2013,",
      "citeRegEx" : "Sharp,? \\Q2013\\E",
      "shortCiteRegEx" : "Sharp",
      "year" : 2013
    }, {
      "title" : "Calculation of Hot Spots for Protein−Protein Interaction in p53/ PMI-MDM2/MDMX Complexes",
      "author" : [ "D.D. Huang", "Y.F. Qi", "J.N. Song", "J.Z.H. Zhang" ],
      "venue" : "J. Comput. Chem. 2019,",
      "citeRegEx" : "Huang et al\\.,? \\Q2019\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2019
    }, {
      "title" : "Interaction Entropy for Protein−Protein Binding",
      "author" : [ "Z. Sun", "Y.N. Yan", "M. Yang", "J.Z. Zhang" ],
      "venue" : "J. Chem. Phys. 2017,",
      "citeRegEx" : "Sun et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Sun et al\\.",
      "year" : 2017
    }, {
      "title" : "Extensive Test of Fixed-Charge Atomistic Simulations",
      "author" : [ "T. Ooi", "M. Oobatake", "G. Nemethy", "H.A. Scheraga" ],
      "venue" : "J. Chem. Theory Comput. 2009,",
      "citeRegEx" : "Ooi et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Ooi et al\\.",
      "year" : 2009
    }, {
      "title" : "Parameters of Hydration of Peptides",
      "author" : [ "D. Eisenberg", "A.D. McLachlan" ],
      "venue" : "Proc. Natl. Acad. Sci. U. S. A",
      "citeRegEx" : "Eisenberg and McLachlan,? \\Q1987\\E",
      "shortCiteRegEx" : "Eisenberg and McLachlan",
      "year" : 1987
    }, {
      "title" : "A New Definition of Cavities",
      "author" : [ "V. Barone", "M. Cossi", "J. Tomasi" ],
      "venue" : "Models. J. Phys. Chem. B",
      "citeRegEx" : "Barone et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Barone et al\\.",
      "year" : 2007
    }, {
      "title" : "Solvation Free Energies by the Polarizable Continuum Model",
      "author" : [ "S. Genheden", "J. Kongsted", "P. Soderhjelm", "U. Ryde" ],
      "venue" : "J. Chem. Phys",
      "citeRegEx" : "Genheden et al\\.,? \\Q1997\\E",
      "shortCiteRegEx" : "Genheden et al\\.",
      "year" : 1997
    }, {
      "title" : "Free Energies Require Explicit Consideration of Binding-Site Hydration",
      "author" : [ "P. Mikulskis", "S. Genheden", "U. Ryde" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Mikulskis et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Mikulskis et al\\.",
      "year" : 2011
    }, {
      "title" : "A Challenging System",
      "author" : [ "H.G. Wallnoefer", "K.R. Liedl", "T. Fox" ],
      "venue" : "GBSA Approach. J. Mol. Model",
      "citeRegEx" : "Wallnoefer et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Wallnoefer et al\\.",
      "year" : 2014
    }, {
      "title" : "Free Energy Prediction for Factor Xa",
      "author" : [ "M. Lepsik", "Z. Kriz", "Z. Havlas" ],
      "venue" : "J. Comput. Chem",
      "citeRegEx" : "Lepsik et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lepsik et al\\.",
      "year" : 2011
    }, {
      "title" : "MM-PBSA Captures Key Role of Intercalating Water Molecules at a Protein−",
      "author" : [ "R.E. Amaro", "J.A. McCammon" ],
      "venue" : "Absolute Binding Free Energy Calculations. Proteins: Struct., Funct., Genet",
      "citeRegEx" : "S. et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "S. et al\\.",
      "year" : 2004
    }, {
      "title" : "Successes, Failures, and Directions for Further Improvement",
      "author" : [ "A. Kohlmann", "X.T. Zhu", "D. Dalgarno" ],
      "venue" : "J. Chem. Inf. Model",
      "citeRegEx" : "Kohlmann et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Kohlmann et al\\.",
      "year" : 2013
    }, {
      "title" : "GB/SA and Watermap to SRC Kinase Inhibitor Potency Prediction",
      "author" : [ "F.C. Lightstone", "S.E. Wong" ],
      "venue" : "ACS Med. Chem. Lett. 2012,",
      "citeRegEx" : "Y. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Y. et al\\.",
      "year" : 2012
    }, {
      "title" : "Calculating Water Thermodynamics in the Binding Site of ProteinsApplications",
      "author" : [ "D. Cappel", "W. Sherman", "T. Beuming" ],
      "venue" : "Binding: The Use of Watermap. Expert Opin. Drug Discovery 2013,",
      "citeRegEx" : "Cappel et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Cappel et al\\.",
      "year" : 2013
    }, {
      "title" : "FEW: A Workflow Tool for Free",
      "author" : [ "N. Homeyer", "H. Gohlke" ],
      "venue" : "PBSA Calculations. Biochim. Biophys. Acta, Gen. Subj",
      "citeRegEx" : "Homeyer and Gohlke,? \\Q2015\\E",
      "shortCiteRegEx" : "Homeyer and Gohlke",
      "year" : 2015
    }, {
      "title" : "Energy Calculations of Ligand Binding",
      "author" : [ "R. Kumari", "R. Kumar", "A. Lynn" ],
      "venue" : "J. Comput. Chem",
      "citeRegEx" : "Kumari et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Kumari et al\\.",
      "year" : 2013
    }, {
      "title" : "Tool for High-Throughput MM-PBSA Calculations",
      "author" : [ "C. Paissoni", "D. Spiliotopoulos", "G. Musco", "A. Spitaleri" ],
      "venue" : "J. Chem. Inf. Model",
      "citeRegEx" : "Paissoni et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Paissoni et al\\.",
      "year" : 2014
    }, {
      "title" : "Computational Alanine Scanning",
      "author" : [ "R. Konecny", "N.A. Baker", "J.A. McCammon" ],
      "venue" : "Comput. Phys. Commun",
      "citeRegEx" : "Konecny et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Konecny et al\\.",
      "year" : 2014
    }, {
      "title" : "ACFIS: A Web Server for Fragment-Based Drug Discovery",
      "author" : [ "Yang", "G. F" ],
      "venue" : "Nucleic Acids Res",
      "citeRegEx" : "B. and F.,? \\Q2016\\E",
      "shortCiteRegEx" : "B. and F.",
      "year" : 2016
    }, {
      "title" : "farPPI: A Webserver for Accurate Prediction of Protein−Ligand Binding Structures for Small-Molecule PPI Inhibitors by MM/PB(GB)SA Methods",
      "author" : [ "F. Zhu", "T. Hou" ],
      "venue" : "Bioinformatics 2019,",
      "citeRegEx" : "Zhu and Hou,? \\Q2019\\E",
      "shortCiteRegEx" : "Zhu and Hou",
      "year" : 2019
    }, {
      "title" : "PBSA_E: A PBSA-Based Free Energy Estimator for Protein−Ligand Binding Affinity",
      "author" : [ "X. Liu", "J. Liu", "T. Zhu", "L. Zhang", "X. He", "J.Z. Zhang" ],
      "venue" : "J. Chem. Inf. Model. 2016,",
      "citeRegEx" : "Liu et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2016
    }, {
      "title" : "Protein−Protein Docking with F2Dock 2.0 and GB-Rerank",
      "author" : [ "R. Chowdhury", "M. Rasheed", "D. Keidel", "M. Moussalem", "A. Olson", "M. Sanner", "C. Bajaj" ],
      "venue" : "PLoS One 2013,",
      "citeRegEx" : "Chowdhury et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Chowdhury et al\\.",
      "year" : 2013
    }, {
      "title" : "Ligand Binding Affinities from MD Simulations",
      "author" : [ "J. Åqvist", "V.B. Luzhkov", "B.O. Brandsdal" ],
      "venue" : "Acc. Chem. Res. 2002,",
      "citeRegEx" : "Åqvist et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Åqvist et al\\.",
      "year" : 2002
    }, {
      "title" : "Forging the Basis for Developing Protein−Ligand Interaction Scoring Functions",
      "author" : [ "Z. Liu", "M. Su", "L. Han", "J. Liu", "Q. Yang", "Y. Li", "R. Wang" ],
      "venue" : "Acc. Chem. Res. 2017,",
      "citeRegEx" : "Liu et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2017
    }, {
      "title" : "Identification and Structure−Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors",
      "author" : [ "V. Santhakumar", "C.H. Arrowsmith", "M. Schapira" ],
      "venue" : "J. Med. Chem. 2018,",
      "citeRegEx" : "Santhakumar et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Santhakumar et al\\.",
      "year" : 2018
    }, {
      "title" : "Characterization of Domain−Peptide Interaction Interface: Prediction of SH3 DomainMediated Protein−Protein Interaction Network in Yeast by Generic Structure-Based Models",
      "author" : [ "T.J. Hou", "N. Li", "Y.Y. Li", "W. Wang" ],
      "venue" : "J. Proteome Res",
      "citeRegEx" : "Hou et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Hou et al\\.",
      "year" : 2012
    }, {
      "title" : "Water, Water Everywhere–except Where It Matters",
      "author" : [ "S.W. Homans" ],
      "venue" : "Drug Discovery Today 2007,",
      "citeRegEx" : "Homans,? \\Q2007\\E",
      "shortCiteRegEx" : "Homans",
      "year" : 2007
    }, {
      "title" : "Toward Clinical Application of the Keap1−Nrf2 Pathway",
      "author" : [ "T. Suzuki", "H. Motohashi", "M. Yamamoto" ],
      "venue" : "Trends Pharmacol. Sci. 2013,",
      "citeRegEx" : "Suzuki et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Suzuki et al\\.",
      "year" : 2013
    }, {
      "title" : "Finding Chemical Drugs for Genetic Diseases",
      "author" : [ "H.-Y. Sun", "T.-J. Hou", "H.-Y. Zhang" ],
      "venue" : "Drug Discovery Today 2014,",
      "citeRegEx" : "Sun et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Sun et al\\.",
      "year" : 2014
    }, {
      "title" : "Acquired Resistance to Crizotinib from a Mutation in Cd74− Ros1",
      "author" : [ "A. Brooun", "L. Friboulet", "D. Huang", "M.D. Falk", "S Timofeevski" ],
      "venue" : "N. Engl. J. Med",
      "citeRegEx" : "L. et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "L. et al\\.",
      "year" : 2013
    }, {
      "title" : "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F",
      "author" : [ ],
      "venue" : "N. Engl. J. Med. 2016,",
      "citeRegEx" : "L,? \\Q2016\\E",
      "shortCiteRegEx" : "L",
      "year" : 2016
    }, {
      "title" : "Somatic and Germline Activating Mutations of the ALK Kinase Receptor in Neuroblastoma",
      "author" : [ ],
      "venue" : "Nature",
      "citeRegEx" : "G,? \\Q2008\\E",
      "shortCiteRegEx" : "G",
      "year" : 2008
    }, {
      "title" : "Model Building of Antibody−Antigen Complex Structures Using GBSA Scores",
      "author" : [ "N. Shimba", "N. Kamiya", "H. Nakamura" ],
      "venue" : "J. Chem. Inf. Model. 2016,",
      "citeRegEx" : "Shimba et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Shimba et al\\.",
      "year" : 2012
    }, {
      "title" : "Predicting the Impact of Missense Mutations on Protein−Protein Binding Affinity",
      "author" : [ "M. Li", "M. Petukh", "E. Alexov", "A.R. Panchenko" ],
      "venue" : "J. Chem. Theory Comput. 2014,",
      "citeRegEx" : "Li et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2014
    }, {
      "title" : "Estimates and Interprets the Effects of Missense Mutations on Protein−DNA Interactions",
      "author" : [ "M. PremPDI" ],
      "venue" : "PLoS Comput. Biol",
      "citeRegEx" : "PremPDI,? \\Q2018\\E",
      "shortCiteRegEx" : "PremPDI",
      "year" : 2018
    }, {
      "title" : "Prediction of Protein−Protein Binding Free Energies",
      "author" : [ "T. Vreven", "H. Hwang", "B.G. Pierce", "Z. Weng" ],
      "venue" : "Protein Sci. 2012,",
      "citeRegEx" : "Vreven et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Vreven et al\\.",
      "year" : 2012
    }, {
      "title" : "Workstations to Workbenches: Towards Predicting Physicochemically Viable Protein−Protein Interactions across a Host and a Pathogen",
      "author" : [ "A. Metz", "E. Ciglia", "H. Gohlke" ],
      "venue" : "IUBMB Life 2014,",
      "citeRegEx" : "Metz et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Metz et al\\.",
      "year" : 2014
    }, {
      "title" : "Methods for Analyzing and Quantifying Protein−Protein Interaction",
      "author" : [ "Syafrizayanti", "C. Betzen", "J.D. Hoheisel", "D. Kastelic" ],
      "venue" : "Expert Rev. Proteomics 2014,",
      "citeRegEx" : "Syafrizayanti et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Syafrizayanti et al\\.",
      "year" : 2014
    }, {
      "title" : "A Human Protein−Protein Interaction Network: A Resource for Annotating the Proteome",
      "author" : [ "H. Goehler", "M. Stroedicke", "M. Zenkner", "A Schoenherr" ],
      "venue" : "Cell",
      "citeRegEx" : "H. et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "H. et al\\.",
      "year" : 2005
    }, {
      "title" : "Are Scoring Functions in Protein−Protein Docking Ready to Predict Interactomes? Clues from a Novel Binding Affinity Benchmark",
      "author" : [ "P.L. Kastritis", "A.M. Bonvin" ],
      "venue" : "J. Proteome Res. 2010,",
      "citeRegEx" : "Kastritis and Bonvin,? \\Q2010\\E",
      "shortCiteRegEx" : "Kastritis and Bonvin",
      "year" : 2010
    }, {
      "title" : "Predicting 3D Structures of Protein−Protein Complexes",
      "author" : [ "I.A. Vakser", "P. Kundrotas" ],
      "venue" : "Curr. Pharm. Biotechnol",
      "citeRegEx" : "Vakser and Kundrotas,? \\Q2008\\E",
      "shortCiteRegEx" : "Vakser and Kundrotas",
      "year" : 2008
    }, {
      "title" : "Revealing the Atomistic Details Behind the Binding of B7−1 to Cd28 and CTLA-4: A Comprehensive Protein−Protein Modelling Study",
      "author" : [ "A. Ganesan", "T.C. Moon", "K.H. Barakat" ],
      "venue" : "Biochim. Biophys. Acta, Gen. Subj. 2018,",
      "citeRegEx" : "Ganesan et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Ganesan et al\\.",
      "year" : 2018
    }, {
      "title" : "Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies",
      "author" : [ "I. Massova", "P.A. Kollman" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Massova and Kollman,? \\Q1999\\E",
      "shortCiteRegEx" : "Massova and Kollman",
      "year" : 1999
    }, {
      "title" : "A Combinatorial Scoring Function for Protein−RNA Docking",
      "author" : [ "Z. Zhang", "L. Lu", "Y. Zhang", "C. Hua Li", "C.X. Wang", "X.Y. Zhang", "J.J. Tan" ],
      "venue" : "Proteins: Struct.,",
      "citeRegEx" : "Zhang et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2017
    }, {
      "title" : "Protein Folding on the Ribosome",
      "author" : [ "L.D. Cabrita", "C.M. Dobson", "J. Christodoulou" ],
      "venue" : "Curr. Opin. Struct. Biol. 2010,",
      "citeRegEx" : "Cabrita et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Cabrita et al\\.",
      "year" : 2010
    }, {
      "title" : "Protein Folding at the Exit Tunnel",
      "author" : [ "D.V. Fedyukina", "S. Cavagnero" ],
      "venue" : "Annu. Rev. Biophys. 2011,",
      "citeRegEx" : "Fedyukina and Cavagnero,? \\Q2011\\E",
      "shortCiteRegEx" : "Fedyukina and Cavagnero",
      "year" : 2011
    }, {
      "title" : "Fragment-Based Quantum Mechanical Calculation of Protein−Protein Binding Affinities",
      "author" : [ "Y. Wang", "J. Liu", "J. Li", "X. He" ],
      "venue" : "J. Comput. Chem. 2018,",
      "citeRegEx" : "Wang et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2018
    }, {
      "title" : "Quantum Mechanical Methods for Drug Design",
      "author" : [ "T. Zhou", "D. Huang", "A. Caflisch" ],
      "venue" : "Curr. Top. Med. Chem. 2010,",
      "citeRegEx" : "Zhou et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2010
    }, {
      "title" : "A Mixed QM/ MM Scoring Function to Predict Protein−Ligand Binding Affinity",
      "author" : [ "S.A. Hayik", "Dunbrack", "R.", "Merz", "K.M." ],
      "venue" : "J. Chem. Theory Comput. 2010,",
      "citeRegEx" : "Hayik et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Hayik et al\\.",
      "year" : 2010
    }, {
      "title" : "Binding Free Energies Calculated with Quantum Mechanics/Molecular Mechanics",
      "author" : [ "C. Protein/Ligand" ],
      "venue" : "J. Phys. Chem. B",
      "citeRegEx" : "Protein.Ligand,? \\Q2005\\E",
      "shortCiteRegEx" : "Protein.Ligand",
      "year" : 2005
    } ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Molecular mechanics Poisson−Boltzmann surface area (MM/PBSA) and molecular mechanics generalized Born surface area (MM/GBSA) are arguably very popular methods for binding free energy prediction since they are more accurate than most scoring functions of molecular docking and less computationally demanding than alchemical free energy methods. MM/PBSA and MM/GBSA have been widely used in biomolecular studies such as protein folding, protein−ligand binding, protein−protein interaction, etc. In this review, methods to adjust the polar solvation energy and to improve the performance of MM/PBSA and MM/GBSA calculations are reviewed and discussed. The latest applications of MM/GBSA and MM/PBSA in drug design are also presented. This review intends to provide readers with guidance for practically applying MM/PBSA and MM/GBSA in drug design and related research fields.",
    "creator" : "PTC Arbortext Advanced Print Publisher 11.1.4300/W Library-x64"
  }
}